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Health care service system is complex both in its complicated delivery design and in 
scientific and regulatory requirement. It is high cost, high risk, dynamic, and unpredictable.  
On one hand, healthcare service providers are challenged by high R&D cost, inefficient 
process management, variability in quality and necessity of changes to avoid the 
unanticipated consequences of new regulations. On the user end, they are overwhelmed by 
the complex service pricing and government regulations, as they often make decisions with 
asymmetric information with little understanding of what’s best and available in the market. 
To help guide providers and users and to advance healthcare service research, we carry out 
theory and practice studies to better understand current issues and provide reasonable 
decision making framework. 
 
In this dissertation, we investigate three broad topics: 1) Network effect on provider and 
customer dynamics. We perform theoretical analysis of health insurance competitions, and 
experimental design of proverse selection and network externality in a generalized 
transaction market. 2) Practice variance and systems analysis for quality and process 
improvement and new clinical guidelines establishment. This includes a system-approach 
study of post-operative care in pediatric congenital heart surgery, and investigation of a 
needle-based epidural procedure in obstetric anesthesia. 3) Computational in-silico drug 
design and its impact to service delivery for day-to-day healthcare needs and response to 
emerging diseases. 
 
We first develop theoretical framework for a two-sided market framework to model 
competition between a Preferred Provider Organization (PPO) and a Health Maintenance 
Organization (HMO). Both health plans compete to attract policyholders and providers. 
Our game-theoretical framework examines the consequences of this risk segmentation on 
xi 
 
providers and the network effect on policyholders based on market information and 
network size. The outcome of competition mainly depends on two effects: a market share 
effect and an adverse selection effect, captured by policyholders’ surplus expectations on 
both policies and copayments. If the adverse selection effect is strong enough, the HMO 
plan takes advantage on competition. On the contrary, if the market share effect dominates, 
the PPO profit is higher in spite of the unfavorable risk segmentation and higher premium. 
Next, we expand our analysis to investigate proverse selection and network externality and 
its effect on consumers and providers in a generalized transaction market. Our framework 
establishes consumer’s utility function and provider’s profit function in terms of network 
indirect externality. We test the responses of both sides using an agent-based model; and 
establish the empirical design to enhance a “balanced” level of consumer’s utility and 
provider’s profit. We highlight a decision support framework for the consumers, the 
providers, along with the market regulators that enables an optimal social welfare.  
 
In the second topic, we aim to analyze patient care process variation to establish new 
clinical guidelines for substantial process and quality improvement. In the post-operative 
care study of congenital heart surgery, we identify and summarize numerous practice 
variations within the post-operative care process. Specifically, we pinpoint various 
process/decision points along the post-op care continuum in which difference in care 
coordination, management, resources and practice may lead to significant impact and 
reasons for the difference in the length of stay among the five clinical sites. Using clustering 
and machine learning approaches, we rank the significance of these factors in predicting 
and influencing the length of stay of the patients. We compare current process to improved 
one using simulation model to demonstrate evidence in LOS improvement. Next, we 
generalize the study to establish and quantify the safety and efficacy of large dose needle-
based epidural technique in obstetric anesthesia. The time and dose required to achieve the 
desired sensory level is quantified. We establish a safe and quickly effective epidural dose 
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that can be administered through the epidural needle prior to the insertion of the epidural 
catheter. Based upon these clinical findings, safe dosage parameters for injections as large 
as 20 milliliters through the epidural needle are quantified. Physician preference for 
medication and dosing levels are contrasted. Understanding the causes and effects of such 
variations can help providers and healthcare organizations in avoiding practices that 
negatively impact outcomes. These findings facilitate the establishment of new epidural 
practice guidelines and delivery improvement. 
 
In the third topic, we describe the first in-silico drug design system model to accelerate 
drug discovery. Our model spans preclinical research, the IND review, clinical research, 
and the NDA review. We identify the global process for any drug discovery pathway with 
timeline along the entire system process. Next, we identify bottlenecks, and perform system 
optimization that offers a holistic view of discovery pathways. The integration of 
bottlenecks into possible candidate tasks which can be conducted simultaneously 
highlights critical paths for the accelerated development process. We define the critical 
paths as parallel model for the new drug development. Our generalized parallel model 
allows not only rapid development but also processes that minimize risk, cost, and time.   
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 CHAPTER I 




For many years, natures of healthcare industry have been considered extremely 
complicated. Recent years have seen numerous complexities, risks or uncertainties in 
healthcare industry. These complicated issues in healthcare industry cause various 
concerns in economic side which should be addressed by healthcare service providers as 
well as healthcare service users. Moreover, clinical practices separately performed by 
various players in healthcare industry do not guarantee the optimal achievements because 
more parameters, variables, and effects have to be taken into account to determine the best 
course of actions. As a result, both theoretical and practical approaches need to be 
maintained to support decision analysis in healthcare industry. The applicability of the 
ideas that both theory and practice are required in decision analysis framework can fill the 
gap between research and clinical practice, which has been considered a major issued in 
evidence-based healthcare. In major clinical areas, it has long been acknowledged that the 
findings of research studies into what is effective often do not translate into actual 
practice[1]. Thus, choosing research approach toward either theory or practice should be 
appropriately addressed to help guide providers and users and to advance healthcare service 
research. In the following sections, we briefly suggest some possible approaches in 
applying theoretical and practical research method. 
 
Network effect on provider and customer dynamics. An important and challenging 
aspect in not only healthcare industry but also outside healthcare entails understanding 
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market structure and its dynamics. Identifying provider and user, setting payment scheme, 
transaction logic can be modeled as microeconomic analysis theory such as game theory 
and two-sided market. With the solutions derived from such theory, we can establish the 
decision analysis strategy to correspond to market dynamics, particularly characterized by 
a network externality when an increase in the number of users/providers increases the value 
to other side. However, these theoretical solutions sometimes do not reflect actual market 
trends. Therefore, with the solutions derived from theoretical study, experimental design 
under various conditions could explain the difference between theoretical solutions and 
actual market dynamics. 
 
Practice variance and systems analysis for quality and process improvement. 
Current healthcare environment is characterized by substantial practice variation – some 
of which have negative consequences in the delivery of recommended care[2-7]. 
Identifying practice variance and the associated processes and/or factors may offer 
opportunities for improving care delivery and clinical outcome. Specifically, 
understanding theoretical background of clinical practice along with identifying various 
process points over the patient care can provide potential of stimulating new ideas for 
investigation or new management techniques, and increases provider’s ability to conduct a 
highly specialized clinical setting. 
 
Computational in-silico drug design. The drug discovery and drug development is 
long, costly and complex process[8]. Implementing new strategy in drug development 
requires practical process innovation to accelerate drug development. Here, theoretical and 
practical approach involves three major pieces 1) identifying critical processes in each 
phase on drug development, 2) building critical process model to accelerate drug 
development, and 3) suggesting possible scenarios to reduce cycle time from beginning to 
marketing in drug development.  
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In this dissertation, we investigate three broad topics: 1) Network effect on provider 
and customer dynamics. We perform theoretical analysis of health insurance competitions, 
and experimental design of proverse selection and network externality in a generalized 
transaction market. 2) Practice variance and systems analysis for quality and process 
improvement and new clinical guidelines establishment. This includes a system-approach 
study of post-operative care in pediatric congenital heart surgery, and investigation of a 
needle-based epidural procedure in obstetric anesthesia. 3) Computational in-silico drug 
design and its impact to service delivery for day-to-day healthcare needs and response to 
emerging diseases. 
 
In the first topic, we first develop theoretical framework for a two-sided market 
framework to model competition between a Preferred Provider Organization (PPO) and a 
Health Maintenance Organization (HMO). Both health plans compete to attract 
policyholders and providers. Our game-theoretical framework examines the consequences 
of this risk segmentation on providers and the network effect on policyholders based on 
market information and network size. The outcome of competition mainly depends on two 
effects: a market share effect and an adverse selection effect, captured by policyholders’ 
surplus expectations on both policies and copayments. If the adverse selection effect is 
strong enough, the HMO plan takes advantage on competition. On the contrary, if the 
market share effect dominates, the PPO profit is higher in spite of the unfavorable risk 
segmentation and higher premium.  
 
Next, we expand our analysis to investigate proverse selection and network 
externality and its effect on consumers and providers in a generalized transaction market. 
Our framework establishes consumer’s utility function and provider’s profit function in 
terms of network indirect externality. We test the responses of both sides using an agent-
based model; and establish the empirical design to enhance a “balanced” level of 
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consumer’s utility and provider’s profit. We highlight a decision support framework for 
the consumers, the providers, along with the market regulators that enables an optimal 
social welfare. 
 
In the second topic, we aim to analyze patient care process variation to establish 
new clinical guidelines for substantial process and quality improvement. In the post-
operative care study of congenital heart surgery, we identify and summarize numerous 
practice variations within the post-operative care process. Specifically, we pinpoint various 
process/decision points along the post-op care continuum in which difference in care 
coordination, management, resources and practice may lead to significant impact and 
reasons for the difference in the length of stay among the five clinical sites. Using clustering 
and machine learning approaches, we rank the significance of these factors in predicting 
and influencing the length of stay of the patients. We compare current process to improved 
one using simulation model to demonstrate evidence in LOS improvement.  
 
Next, we generalize the study to establish and quantify the safety and efficacy of 
large dose needle-based epidural technique in obstetric anesthesia. The time and dose 
required to achieve the desired sensory level is quantified. We establish a safe and quickly 
effective epidural dose that can be administered through the epidural needle prior to the 
insertion of the epidural catheter. Based upon these clinical findings, safe dosage 
parameters for injections as large as 20 milliliters through the epidural needle are quantified. 
Physician preference for medication and dosing levels are contrasted. Understanding the 
causes and effects of such variations can help providers and healthcare organizations in 
avoiding practices that negatively impact outcomes. These findings facilitate the 




In the last topic, we describe the first in-silico drug design system model to 
accelerate drug discovery. Our model spans preclinical research, the IND review, clinical 
research, and the NDA review. We identify the global process for any drug discovery 
pathway with timeline along the entire system process. Next, we identify bottlenecks, and 
perform system optimization that offers a holistic view of discovery pathways. The 
integration of bottlenecks into possible candidate tasks which can be conducted 
simultaneously highlights critical paths for the accelerated development process. We 
define the critical paths as parallel model for the new drug development. Our generalized 
parallel model allows not only rapid development but also processes that minimize risk, 








An important and challenging aspect in not only healthcare industry but also outside 
healthcare entails understanding market structure and its dynamics. Identifying provider 
and user, setting payment scheme, transaction logic can be modeled as microeconomic 
analysis theory such as game theory and two-sided market. With the solutions derived from 
such theory, we can establish the decision analysis strategy to correspond to market 
dynamics, particularly characterized by a network externality when an increase in the 
number of users/providers increases the value to other side. However, these theoretical 
solutions sometimes do not reflect actual market trends. Therefore, with the solutions 
derived from theoretical study, experimental design under various conditions could explain 
the difference between theoretical solutions and actual market dynamics. 
 
In this chapter, we perform theoretical analysis of health insurance competitions, 




2.1 Competition Strategy for Healthcare Insurance Plans 
 
In this section, we first develop theoretical framework for a two-sided market framework 
to model competition between a Preferred Provider Organization (PPO) and a Health 




The health insurance exchanges established by the Affordable Care Act(ACA) opened in 
October 2013, potentially auguring a new era for the insurance industry and American 
health care overall[9]. Approximately eight million US residents currently obtain private 
health insurance coverage through one of the marketplaces created by ACA[10]. When 
fully implemented, the ACA is expected to increase the number of Americans with 
insurance by more than thirty million[11]. One of the key aspects of the ACA is new era 
of the health insurance marketplace where consumers can shop for private plans with 
different cost sharing. Taking account this aspect, consumers would expect various choices 
and appropriate premiums from health insurance marketplace. However, consumers’ 
selection pools have been restricted since ACA was initiated because insurers use restricted 
or “narrow” provider networks in marketplace plan[12]. Actually, insurance plans that only 
allow coverage for a limited set of providers are growing in popularity under ACA[13]. 
Insurers are likely to continue to use narrow networks as a strategy to keep premiums 
affordable. These limited networks, which can steer consumers to lower cost providers, 
have been proposed as a solution to rising health care costs[14]. One of the reasons why 
insurers prefer to keep the “narrow network” strategy is fear of adverse selection which 
might be happened in the health insurance exchange market. Adverse selection is often 
presented as a major problem for competitive health insurance markets[15]. This 
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phenomenon occurs when premiums set by health plans do not perfectly reflect the 
heterogeneity in policyholders’ health risk. In health insurance markets, the complicating 
factor is risk segmentation. This imperfect risk adjustment can be caused by different 
reasons. For example, it may be impossible or too costly for insurers to set differentiated 
premiums taking into account the risk factors that would reflect this heterogeneity[16]. 
Also, the regulation of health insurance exchange settled by current ACA prevents health 
plans from setting discriminated premiums in an individual risk adjustment fashion. 
Moreover, when policyholders subscribe health insurance contracts linked to their jobs, 
employers often supply a menu of health insurance plans with pre-set employee 
premiums[17]. In this case, health plans’ premiums reflect differences in average total cost 
and not in individual expected health expenditure.  
 
Traditional economics would suggest that the entry of more insurance plans into 
the health plan exchange market would lead to premium competition among the plans as 
each tries to get the policyholders’ contracts. Premiums would get bid down to marginal 
costs. However, the nature of health insurance competition is more complex than this 
traditional model. Cutler and Reber observed that policyholders might be tempted, in an 
attempt to look for health plans that supply coverage with the lowest possible premium, to 
withdraw from plans that attract higher risks than himself[18]. In a dynamical setting, this 
behavior can lead to a “death spiral” phenomenon whereby less restrictive plans attract 
high risks and therefore repel low and medium risks, with a cumulative effect[19]. It is 
commonly acknowledged that high risk policyholders choose generous plans whereas low 
risks seek lower prices[20]. Since premiums are set by the average cost of a health plan’s 
policyholders, the expected surplus of a policyholder depends on the characteristics of the 
other enrollees. This nature of the expected surplus can explain why “death spiral” happens 




Another component of health insurance plan selection has to do with the structure 
of insurance products, which introduces both path dependence and nonlinearity into the 
decision problem through various contractual components such as deductibles, out-of-
pocket maximums, coinsurance and copayment options, and different treatment of 
providers that are preferred or non-preferred under the insurance policy[21]. Also, the 
decision problem relates to the policyholder’s personal preferences and behavior. For 
example, there is a tendency for higher risk consumers to select PPOs and lower risk 
policyholders to enroll in HMOs[18, 19, 22, 23]. Bardey and Rochet first attempted to 
model the two-sided nature of the health plans’ competition characterized by indirect 
network externalities between providers and policyholders’ sides[16]. They consider an 
asymmetric duopoly situation to model competition between a PPO and an HMO. However, 
they focus on the case where health plans do not compete for the same physicians, therefore 
the two health plans have access to distinct pools of physicians. Gollier analyzes optimal 
insurance contract when the policyholder faces uncertainty about the distribution of his 
potential health risk[24]. Another research on asymmetric information in insurance market 
under two-sided market structure has been conducted and it concludes that competition 
cannot work properly and actuarially fair insurance is almost impossible[25]. Taking 
premium and copayment into account together, two-part pricing contract has been 
investigated to cover different types of policyholders[26].  
 
In this paper, we develop theoretical framework for a two-sided market framework 
to model competition between a Preferred Provider Organization (PPO) and a Health 
Maintenance Organization (HMO). Both health plans compete to attract policyholders and 
providers. Our game-theoretical framework examines the consequences of this risk 
segmentation on providers and the network effect on policyholders based on market 
information and network size. The outcome of competition mainly depends on two effects: 
a market share effect and an adverse selection effect, captured by policyholders’ surplus 
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expectations on both policies and copayments. If the adverse selection effect is strong 
enough, the HMO plan takes advantage on competition. On the contrary, if the market 
share effect dominates, the PPO profit is higher in spite of the unfavorable risk 
segmentation and higher premium. 
 
2.1.2 The Model Structure 
 
Three kinds of players are considered in the model. On the demand side, policyholders can 
become sick with an exogenous probability  , which is heterogeneous across 
policyholders. The probability   is distributed on (0, 1) with pdf f  and cdf F . On the 
provider side, physicians may decide to be affiliated with a health plan or not, according to 
the remuneration( R ) offered. If physicians are affiliated with PPO, they only accept 
policyholders who have PPO plan, that is in-network patients only. Meanwhile, physicians 
who choose to be with HMO can accept PPO out-of-network patients as well as HMO in-
network patients. There are two health plans between policyholders and physicians, 
indexed by i , with  HPi ,  represents  HMOPPO ,  accordingly. Two health plans 
compete in health insurance contracts to attract policyholders and purchase healthcare 






Once potential policyholders approach health insurance market, PPO and HMO 
provide their premiums iP  and proportion of physicians (between 0 and 1) affiliated with 
network i  which is denoted in . Thus, a higher in  means more choices. If policyholders 
choose PPO, then copayment is incurred whenever they visit physicians. For the simplicity, 
we assume that there is no copayment in HMO plan. Actual HMO insurance plan generally 
charges small amount of copayment and no deductible on policyholders but they are 
negligible compare to PPO’s copayment and deductible charge on policyholders.  
 
Following Bardey and Rochet[16], we adopt their utility function for the 
policyholder. PPO policyholder’s utility function is: 
  PHPHHPPP PccnnU                                        2.1.1 
and HMO policyholder’s utility function is: 
HHHH PnU                                                      2.1.2 
where iP  is premium charged by each plan and in  is proportion of physicians affiliated 
with plan i . Pc  is copayment when PPO policyholder visits in-network physician and Hc  
Figure 2- 1. Two-Sided Healthcare Insurance Market 
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is copayment when he visits out-of-network physician. Finally, P  is policyholder’s 
surplus derived from proportion of PPO network physicians which captures how 
policyholder values potential access to the affiliated physicians. Likewise, H  is 
policyholder’s surplus derived from proportion of HMO network physicians.  
 
 We assume that health insurance plans are profit-maximization entities. The profit 
function of health insurance plan i  is: 
      iiii TPD                                                         2.1.3  
where iD  is the number of policyholders affiliated with plan i  and iT  the total transfer 
paid to physicians. 
 
2.1.3 The Outcome of Competition Between Health Insurance Plans 
 
We first analyze the determination of risk segmentation on policyholders’ side. Then, we 
conduct physicians’ side analysis. Finally, we find the global market equilibrium. 
 
Risk Segmentation on the Policyholders’ side 
On the policyholders’ side, the market shares between the PPO and the HMO, PD  and HD  
respectively, decide the risk segmentation. Since we assume that higher risk policyholders 
tend to choose the PPO rather than the HMO, marginal indifferent level of policyholders 
between the PPO and the HMO is: 
   HHHPPP nPUnPU ,,  . 
 
Therefore, the marginal policyholder’s type 
~
 is the one who is just indifferent 
between the PPO and the HMO: 
13 
 










.                                      2.1.4 
 
Physicians’ Affiliation to Insurance Plans 
Basically, we assume that each health plan has access to distinct groups of physicians. 
However, since the PPO policyholders can access out-of-network, physicians who are 
affiliated with the HMO can generate profit from both groups of policyholders. We adopt 
Bardey and Rochet model to understand physicians’ side logic, which the number in  of 
physicians who affiliated to health plan i  is only function of the net profit level i  offered 
by each health plan[16]. We assume that physicians uniformly located on a (0, 1) interval 
like Hotelling model and incur a transaction cost proportional to their distance with the 






where   captures the transaction cost of the physicians and the sensitivity of the physicians’ 
willingness to accept payment schemes offered by each health plan. If physicians are 
affiliated with plan i , they generate profit from a fee-for-service rate iR  offered by plan i  
and copayment ic  paid by the PPO policyholders.  
 













                                             2.1.5 
and 













.                               2.1.6 
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Particularly, formula 2.1.5 shows the possibility of indirect network externality in the PPO 
plan. In other word, physicians who are affiliated with the PPO expect higher profit from 
the number of the PPO policyholders if the upper tail of the risk distribution is thick enough.  
 
 Thus, health plans should coordinate the level of iP  and ic  on the policyholders’ 
side and the level of iR  and ic  on the physicians’ side. We assume that each health plan 
has distinct groups of physicians, thus: 





 dFRcn PPP                                                2.1.7 
and 








 dFRcdFRn PHHH .                                2.1.8 
 
The Health Insurance Plans’ Profits and Maximization Problem 
Using 2.1.7 and 2.1.8, the health insurance plans’ profits are: 






1 PPPPPPPPP ndFcPFdFRPFTPD 

  , 
and  







 dFccnnPFdFRPFTPD PHHPHHHHHHH . 
 
 Each plan selects  ii nP ,  to maximize its profit. The first-order conditions with 
respect to PP  and HP  are: 




























 ,  
and  






































































.                                            2.1.10 
  
Using equation 2.1.4, we obtain: 
   
 
 



























.      2.1.11 
 
 The first-order conditions with respect to Pn  and Hn  are: 






























 ,  
and  






























Using equation 2.1.9, 2.1.10, and 2.1.11 with  










































 .                                                                                                    2.1.13 
 Using equations 2.1.7 and 2.1.8, we find the fee-for service rates as: 








,                                                                                            2.1.14 
and 









































 .                                2.1.15 
  


































































.                   2.1.17 
 
 By replacing premiums and physicians’ numbers by their outcomes in the health 
insurance plans’ profits, we obtain the profits: 
    
 
      
 
    
 
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.                     2.1.19 
 
2.1.4 Analysis of the Outcomes  
 
In this section, we analyze the meaning of the outcomes in the above section. First of all, 
the market segmentation determined by policyholders’ risk level is found as equation 2.1. 
11. We assume that iin  is large enough so that iii cn   is always positive. Since the 
marginal policyholder’s type 
~
lies on (0, 1), equation 2.1.11 is: 
   
 
 





























 ,  
and it means  
2
1~
F  . Therefore, the demand of the PPO, PD , is always more than a half 
of the market. In other word, the market share of the PPO is always higher than the HMO 
under two-sided market competition. Recent industry report supports our finding that fifty-
two percent of covered workers are enrolled in PPOs in 2015. The PPO’s market share in 




Figure 2- 2. Distribution of Health Plan Enrollment for Covered Workers, by Plan Type, 
1988-2015. Source: Kaiser, KPMG and HIAA 
 
 Secondly, we investigate the implications of physicians’ affiliation with each plan. 






Fnn HPHP  .                                       2.1.20 
We assume that the expected surplus of the HMO policyholder, H  is larger than the others, 
P . When people choose the HMO rather than the PPO, they tend to believe that less 
flexible services offered by the HMO are substantially workable for their health risks[18]. 
With equations 2.1.12, 2.1.13 and 2.1.20, the affiliated numbers of physicians for each plan 
depends on both indirect network externalities described by market segmentation and direct 
network externalities described by policyholders’ valuations on physicians’ side. More 
specifically on policyholders’ valuations, if the expected surplus of the HMO network 






HP  , then the size of the PPO physicians’ network ( Pn ) is bigger than the size 
of the HMO physicians’ network ( Hn ). If the expected surplus of the HMO network access 
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H  , 
then the size of the HMO physicians’ network ( Hn ) is bigger than the size of the PPO 
physicians’ network ( Pn ). Therefore, we can find that the physicians’ side prefers to join 
the PPO when the market share effect dominates on the policyholders’ side while the 
physicians’ side prefers to join the HMO when the adverse selection effect dominates on 
the policyholders’ side.  
 
 Thirdly, we analyze the conditions how each health insurance plan offers 
remunerations to the affiliated physicians’ group. We assume that in-network copayment 
pc  is less than out-of-network copayment Hc . From equations 2.1.14 and 2.1.15, pR  is 










H  . Thus, 
similar standard also can be held in remuneration scheme likewise physicians’ network. If 
the market share effect dominates, the PPO offers higher fee-for-service level, pR , to 
maintain bigger size of affiliated physicians’ group while if the adverse selection effect 
dominates, then the HMO offers higher fee-for-service level, HR . 
 
 Finally, each health insurance plan’s profit is determined as equation 2.1.18 and 
2.1.19. Then, 
         
 




























where  ~  is function of probability distribution,   1~0   . In this analysis, the similar 






HP  , the profit of the PPO is higher while if the adverse selection effect 
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H  , the profit of the HMO is higher. It is worth to denote the 
role of the copayments even though the copayments are significantly less than premiums. 
Recall that in-network copayment pc  is less than out-of-network copayment Hc . The last 
term    ~ PH cc  is only related on the PPO plan. If the PPO sets out-of-network 
copayment, Hc , to be too high, then the PPO makes losses on own profit. Although the 
lower level of out-of-network copayment might not directly harm the profit of the PPO 
directly, we might conject that the HMO could have flexibility in the market because the 
HMO can offer more attractive remuneration to the physicians’ side and premium to the 
policyholders’ side. Therefore, it is required for the PPO to maintain appropriate ratio 





In this paper, we analyze the outcome of competition between a PPO and an HMO. Our 
framework helps identify conditions how each plan can benefit competitive advantage 
corresponding two-sided market competition. We identify the two conditions: the market 
share effect described by segmentation of the policyholders supports the PPO’s higher 
profit whereas the adverse selection effect described by the policyholders’ higher 
expectation on the HMO plan leads the HMO’s competitive advantage.  
 
 As mentioned in Bardey and Rochet[16], the two-sided market approach in 
healthcare insurance industry provides some important implications for public policy 
issues. The two-sided nature of health insurance market can explain the preference of 
higher flexibility that has been observed during the last 15 years in the US health insurance 
21 
 
market. However, current ACA prevents the insurance company from setting discriminated 
premiums in an individual risk adjustment fashion. We believe that the restriction of 
offering flexibility is the one of reasons why recent drop off rate increases in the health 
insurance exchange settled by ACA. The regulation needs to address two-sided logic in 
health insurance market rather than using one-sided logic. In such a context, policyholders 
can choose the plans according to their preferences and insurance plans may expand “wide 
network” strategy to benefit from competitive advantage. 
 
Acknowledgment 




2.2 Experimental Design of Proverse Selection and Network Externality 
 
In this section, we expand our analysis to investigate proverse selection and network 




Two-sided market models provide a new perspective to view the platform-based industry 
such as credit cards, newspapers, telecommunications, internet services, computer 
operation systems and many more. Recent technology advances drive more industries to 
adopt two-sided market transactions. One of the reasons to adopt two-sided market 
transactions is network externality. Product and services that bring together groups of users 
in two-sided networks are platform[27]. They provide infrastructure and rules that facilitate 
the two groups’ transactions and can take many guises. In some cases, platforms rely on 
physical products. In other cases, they are places providing services, like web sites or 
mobile connections. A key characteristic, here, is the presence of network externalities 
between these two groups. In markets with two-sided network externalities, the value that 
a group derives from joining a platform is determined by the number of the other group[28].  
 
 Most theories of network externalities are originated from the insight that 
characterizing network markets may require not only product standardization, essential to 
demand economies of scale[29, 30], it may also require recognizing sharp distinctions 
between consumer types[31]. With the network externalities addressed on historically, 
recent two-sided market literature has shown various implications such as pricing[32-38], 
competition strategy[39-43] , and market structure[27, 28, 37, 44-46]. In addition to two-
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sided market literature, network externalities based on new technology adoption have been 
investigated[47-49].  
 
 However, markets with network externalities sometimes experience negative 
results because of the adverse selection behavior chosen by any distinct group in the market. 
Since Akerlof first formalized the theory of adverse selection[50], numerous researches 
have been aware of the potential for adverse selection in markets with information 
asymmetries[51]. In particular, healthcare insurance markets[16, 52-54], healthcare service 
markets[55], auctions[51], and financial asset markets[56, 57] have been emphasized that 
they might experience market failures that adverse selection can cause. Therefore, methods 
to detect adverse selection and avoid it are truly required for the policy makers as well as 
the groups in the market.  
 
 Another issue on network externalities is how they affect the diffusion and the 
consequent economic value associated with transaction. Despite the sizeable academic 
literature on the dynamics of network markets, the answer to this issue is not obvious[58]. 
One side of literature suggests that network effects drive faster market growth due to 
increasing returns associated with such processes. The other argues that networks can also 
create the opposite effect of slowing growth. For example, most consumers see little utility 
in the transactions, as there are few others both in the consumer group and in the provider 
group, and so they may take a “wait-and-see” strategy until there are more players in the 
market. In addition, we may observe that some of users tend to abandon the network market 
even after the diffusion and growth has been boosted. Recently, we see that Facebook and 
Twitter are losing users even though the contents providers based on them are still 
increasing. It is pretty interesting that this phenomenon is against the literature about the 




 Therefore, there are important question to arise, 1) how to internalize the effects of 
network externality in the market, 2) with potential negative side of network externality, 
how to avoid adverse selection in the networked market and 3) as a result, how to establish 
a market structure that provides “proverse selection” which is characterized by benefits of 
network externality among participants in the market. In this paper, we first describe the 
theoretical model as we applied it to market transaction taking into account two-sided 
market structure reflecting on the network externality. Then, we establish the empirical 
design, with agent-based model, to enhance a “balanced” level of consumer’s utility and 
provider’s profit. We highlight a decision support framework for the consumers, the 
providers, along with the market regulators that enables an optimal social welfare. 
 
2.2.2 The Theoretical Model 
 
Platform 
We consider a monopoly platform of a two-sided market. A platform provides market place 
where consumers and providers are connected with. The platform collects a subscription 
price p  from each consumer who is willing to purchase services or products through the 
platform. Also, the platform collects a subscription price s  from each provider to allow 
the services or products to reach the consumer. We assume that the platform only offers 
linear fee contracts, thus it does not offer any quantity discounts or exclusive contracts such 
as lump-sum fees and incentives. Finally, we assume that the cost of providing the platform 
service is c  per consumer.  
 
Consumers 
Consumers are interested in accessing the platform to reach services or products from 
providers. A consumer i ’s location ix , indexes his utility for accessing the platform and 
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interacting with providers. Consumers pay a “transaction cost” t  per unit of distance 
“traveled.” Consumers’ locations are uniformly distributed on the interval (0, 1) with the 
platform located 0x  based on a generalized Hotelling model. This modeling setup is a 
common way in the two-sided market model and is consistent with Armstrong[59].  
  
Consumer i ’s utility is specified as: 
ptxbnvu ipi                                                     2.2.1 
where cv   is an intrinsic value that a consumer receives from accessing the platform 
irrespective of the amount of services/products, b  is the marginal value that a consumer 
places on an additional provider on the platform and pn  is the number of providers 
connected with the platform.  
 
Providers 
Providers depend on transaction revenue per consumer, a , to generate revenue. We assume 
providers to be uniformly distributed on the unit interval and have a unit mass. We make 
the simplifying assumption that providers do not compete with each other. Each provider 
then earns can , where cn  is the number of consumers paying the platform for access to 
providers. Thus, a  is the value for a provider of an additional consumer connected with 
the platform.  
 
 Providers are heterogeneous in terms of the fixed costs of coming up with a 
business idea and setting up their business. A provider indexed by j  faces a fixed 
“transaction” cost of jfy , where jy  is the index of the provider’s location on the unit 
interval (0, 1). Each provider may have to pay the platform a subscription fee, s , to gain 
access to consumers. Hence, a provider j ’s profit is: 
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sfyan jcj  .                                                 2.2.2 
 
Demand 
In this two-sided market, the demand for service/product relies on the expected amount of 
service/product provided since more consumers will connect to the network if more 
expected content is available. Moreover, the provision of service/product depends on the 
expected number of consumers. When the expected number of consumers is 
e
cn  and the 
expected number of providers is e
pn , the marginal consumer ix  who is indifferent between 
subscribing to the platform not subscribing is located at: 








 .                                                2.2.3 









 .                                                  2.2.4 
 
 We focus equilibrium expectations where each side’s expectations are met. That is, 
c
e
c nn   and p
e
p nn  . The number of consumers and providers is then given by the 

















, .                                                                                                  2.2.6 
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Positivity of the demands requires abft  , and v  to be sufficiently large, that is  
f
bs
pv   and 
a
ts
pv  . 
 
Monopoly Platform Optimum 
We now describe the monopoly platform optimum. The platform maximizes its profit with 
subscription prices, p  and s : 
       spsnspncpspMax pc ,,,                                     2.2.7 
where c  is platform’s service cost for consumer. 




, which is: 
 






 ,                                                                                              2.2.8 












 .                                                                                              2.2.9 
 
Solving equation 2.2.8 and 2.2.9 simultaneously, we can find the subscription 











 ,                                    2.2.10 
and 






 .                                              2.2.11 
 











 ,                                             2.2.12 







 .                                               2.2.13 
 












 .                                          2.2.14 
 
2.2.3 The Experimental Model 
 
In order to examine how network externality drives market transactions, we use an agent-
based modeling technique that simulates aggregate consequences derived from interactions 
between groups in the market. Agent-based models(ABM) are used to map actual situations 
in a “would-be-world” while keeping realistic relationships accurate at the individual 
level[58]. They are increasingly used in the several fields to model actual processes such 
as diffusion, collective action, and group influence[60, 61] as well as economic activity in 
general[62-64]. They are also increasingly used in the marketing literature, particularly 
with respect to new product growth[65-70].  
 
 Kiesling et al. suggested four methodological strengths of the ABM: 1) the ability 
to explicitly model decision making entities individually, 2) the ability to account for the 
interactions between entities, 3) the ability to address what-if-type questions, and 4) the 
ability to capture emergent market dynamics[63]. Since our research on network 
externality contains decision making and market dynamics as well as interaction among 
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multiple entities, the ABM technique enables us to contribute to establish a decision 
support framework for the consumers, the providers, along with the market regulators that 
enables an optimal social welfare.  
 
Simulation Procedure 
First of all, we assign all parameter values for the simulation. We assume that each 
consumer acts reasonably based on utility function from equation 2.2.1. Likewise, each 
provider follows equation 2.2.2. Both consumer and provider join the platform to make 
transaction observing the numbers of the other side. All parameter values are shown in 
table 2.1. 
 
Table 2- 1. Parameter values in ABM simulation 
 Consumer Provider Platform 
Parameters 
Intrinsic value( v ) :  
 fixed value 
 Service cost( c ) :  
 fixed value 









Transaction cost( t ) :  
 fixed value 
Transaction cost( f ) :  
 fixed value 
 
Consumer location( ix ): 
 Uniform 
Provider location( iy ): 
 Uniform 
 
Subscription price( p ): 
 fixed value 
Subscription price( s ): 





 Once the all parameter values are assigned, we generate simulation procedure 
increasing numbers of each side, i.e. consumer group and provider group. Then simulation 
procedure calculates utility value of each consumer based on numbers of provider group. 
Likewise, the procedure calculates the profit of each provider based on numbers of 
consumer group. Whenever transactions happen between consumers and providers, 
platform’s profits are generated in terms of the numbers of both sides. In addition, the ABM 
simulation procedure generate additional measures to support market regulator’s reactions. 
We adopt total surplus(TS) as a social welfare’s standpoint, which is: 
Total Suplus(TS)  
= Platform’s Profits    + Consumer’s Surplus(CS) + Total Provider’s Profits  p  




















Finally, we arbitrary maintain ratio between consumer and provider as 10:1. As a 
result, our ABM simulation runs until there exist 500 consumers and 50 providers who 




In this section, we describe our findings on each entity based on ABM simulation group 
and interpret the implications.  
 
Consumer 
Now, we turn to the simulation results on consumer side. We test three different scenarios 
based on assigned parameter values. Figure 2-3 shows our ABM simulation results in 
consumer utility. First, we observe the three different stages, which we call them stage 1, 
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2 and 3. At stage 1, each consumer utility from all three scenarios gradually increases, 
practically very little deviation exists. At stage 2, the tendency of all scenarios is increasing 
but the shape of each scenario is different. Consumer’s utility increases sharply in scenario 
1 and 2 while it increases gradually in scenario 3. Also, the deviation of the scenario 2 is 
larger than the scenario 1. At stage 3, consumer’s utility derived from each scenario does 
not increase any more. Consumer’s utility from scenario 1 and 2 decreases as the numbers 
of provider still increases, particularly scenario 2 shows sharp drop down at stage 3. 
Meanwhile, consumer’s utility from scenario 3 stays consistent level even the numbers of 
provider still increases.  
 
 The results in Figure 2-3 provide three clues in network externality. First of all, 
gradual increase of the consumer utility in stage 1 shows that “chilling effect” exists in 
two-sided market transaction. Initial network externality may have a chilling effect on 
growth due to the “wait-and-see” position adopted by consumers in unmatured market. We 
can interpret that the very low growth rate of consumer utility proves that two-sided market 
structure also experiences chilling effect in the early stage of transactions. Therefore, 
companies who start up their business under two-sided market structure should induce 
more providers to affiliate with them. Secondly, explosion of the consumer utility in stage 
2 shows that there exists indirect network externality effect in two-sided market structure. 
Finally, the finding in stage 3 is very interesting. The numbers of provider reach maximum 
level does not guarantee the maximum level of consumer utility. When the numbers of 
provider are large enough, consumer may be suffered from asymmetric information, which 
generally happens in networked market. Previous literature points out possibility of adverse 
selection caused by asymmetric information, in particular, when provider group has more 
information than consumer group. The tendency in stage 3 could reflect the possibility of 
adverse selection adopted by consumer. That is, too many providers exist in the market 
does not guarantee the maximizing consumer utility level. Hence, platform or market 
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regulator needs to control the numbers of provider at appropriate level. We will show this 
reasoning in social welfare analysis again.  
 
 
Figure 2- 3. Simulation results: consumer utility 
 
Provider 
Simulation results on provider side are rather straightforward. Figure 2-4 shows our ABM 
simulation results about provider profits. All three scenarios on provider profits increase 
steadily as the numbers of consumer increase. Provider can fully internalize the indirect 
network externality to generate its profits under two-sided market structure. Therefore, 
provider always expects the maximum profits when the numbers of consumer who affiliate 








Next, we generate platform profits as the numbers of both sides change. Figure 2-5 shows 
the platform profits with the numbers of both sides. As we expect, platform profits have 
positive relationship with the numbers of consumer because platform can collect more 
subscription fee from providers as the numbers of consumer increase. However, platform 
profits do not increase any more when too many providers join the platform. Since 
consumer utility may drop down if there are too many providers in the market, some 
consumers choose not to affiliate with the platform rather than choose to make transactions 
through the platform. Then, the platform may experience profits to be falling down from 
the maximum profits level.   
 
 To prevent loss of profits, platform may choose two options. First one is preventing 
consumers from adverse selection. Platform may provide additional information balancing 
the status of asymmetric information on consumers’ side. Informed consumers do not need 
to deviate from transactions through the platform, so the platform can maximize its profits. 
Figure 2- 4. Simulation results: provider profits 
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Second option is controlling the numbers of provider. If the platform recognizes decreasing 






Finally, we describe implications on regulator’s standpoint. We use total surplus generated 
under two-sided market structure. Figure 2-6 shows the ABM simulation result in total 
surplus. Total surplus consists of three parts: platform profits, accumulated consumers’ 
utility and total providers’ profits. Therefore, total surplus in this market increases as the 
numbers of consumer increases because of platform profits and provider profits generated 
by the numbers of consumer. However, we can observe the decrease of total surplus even 
the numbers of provider still increase because they can affect consumer’s utility and 
platform profits negatively. Hence, regulator needs to restrict the numbers of provider in 
the market. That is, too many providers in the market is not socially optimum. Proverse 
selection happens under appropriate numbers of provider.  
 








This paper focuses on understanding and analyzing proverse selection and network 
externality in two-sided networked market structure. We aim to identify effects from 
network externality and the associated behaviors that may offer opportunities for enjoying 
positive effects derived from network externality. First of all, we introduced monopoly 
two-sided market where general transactions occur between consumers group and 
providers group through the platform. Based on equilibriums under monopoly two-sided 
market structure, we ran agent-based model simulation to identify each entity’s behavior 
taking account into network externality. 
 
Figure 2- 6. Simulation result: total surplus 
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 Our study reveals several intuitive results. First, a consumer can hesitate to make 
transactions with providers when the maturity of the two-sided market is early stage. Since 
consumer cannot be certain about the positive effect of network externality in terms of 
small numbers of provider, consumer can take wait-and-see strategy until enough numbers 
of provider access the platform. We can interpret that this chilling effect in the network 
externality causes troubles for startup companies who adopt two-sided market platform 
business. Secondly, both consumer and provider can fully internalize network externality 
once both sides have enough numbers in the market. Therefore, positive indirect network 
externality effect exists in the two-sided market structure. Thirdly, once the two-sided 
market is grown up, some consumers may deviate from the market transactions under 
adverse selection effect. Therefore, the platform needs to balance the information on both 
sides to maintain proverse selection strategy. Finally, regulator may choose to restrict entry 
of additional providers in the market to facilitate social optimum. Since we show the 
possibility of consumer’s adverse selection, social optimum can be managed under 
appropriate numbers of provider.  
 
 Our experimental framework using agent-based model provides practical decision 
making model for both platform and regulator to manage proverse selection and social 
optimum. However, our model currently focuses on monopoly two-sided market structure. 
We expect two potential extensions from our model: 1) competitions between platforms 
and 2) social influence in network externality.  
 
 In conclusion, we see this paper as a starting point for studying the network 
externality under generalized two-sided market structure. We believe that our model 
highlights a decision support framework for the consumers, the providers, along with the 





PRACTICE VARIANCE AND SYSTEMS ANALYSIS FOR 
QUALITY AND PROCESS IMPROVEMENT  
 
 
Current healthcare environment is characterized by substantial practice variation – some 
of which have negative consequences in the delivery of recommended care[2-7]. 
Identifying practice variance and the associated processes and/or factors may offer 
opportunities for improving care delivery and clinical outcome. Specifically, 
understanding theoretical background of clinical practice along with identifying various 
process points over the patient care can provide potential of stimulating new ideas for 
investigation or new management techniques, and increases provider’s ability to conduct a 
highly specialized clinical setting. 
 
 In this chapter, we discuss two topics. Section 3.1 discusses practice variations 
within the post-operative care process. Specifically, we pinpoint various process/decision 
points along the post-op care continuum in which difference in care coordination, 
management, resources and practice may lead to significant impact and reasons for the 
difference in the length of stay among the five clinical sites[71]. In Section 3.2, we 
generalize the study to establish and quantify the safety and efficacy of large dose needle-
based epidural technique in obstetric anesthesia. We establish a safe and quickly effective 
epidural dose that can be administered through the epidural needle prior to the insertion of 
the epidural catheter[72].  
 This chapter consists of content from two full papers, “Practice Variance Analysis 
for Process Improvement in Post-Operative Care of Congenital Heart Surgery, authored by 
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Eva K. Lee, Jinha Lee, Susan C Nicolson, Richard G Ohye, Lara S Shekerdemian, Madolin 
K Witte, Prashant D. Tailor, and William Mahle; and Investigating a Needle-Based 
Epidural Procedure in Obstetric Anesthesia, by Eva K Lee, Haozheng Tian, Jinha Lee, Xin 
Wei, John Neeld, Jr. K Doug Smith, and Alan R Kaplan. 
 
3.1 Practice Variance Analysis for Process Improvement in Post-Operative 
Care of Congenital Heart Surgery 
 
This section consists of the entire paper, “Practice Variance Analysis for Process 
Improvement in Post-Operative Care of Congenital Heart Surgery,” that is submitted to 
Circulation. 
 
Practice Variance Analysis for Process Improvement in  
Post-Operative Care of Congenital Heart Surgery  
 
Eva K. Lee, PhD *,1,2,3, Jinha Lee1,2,3, Susan C Nicolson, MD6,7, Richard G Ohye, MD8,9, Lara S 
Shekerdemian, MD10,11, Madolin K Witte, MD12, Prashant D. Tailor1,2,3 ,William Mahle, MD4,5 
1Center for Operations Research in Medicine and HealthCare, 2NSF I/UCRC Center for Health Organization 
Transformation, 3Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA, 4Children’s 
HealthCare of Atlanta, 5Emory University School of Medicine, Atlanta, GA, 6The Children's Hospital of Philadelphia, 
7University of Pennsylvania School of Medicine, Philadelphia, PA, 8C. S. Mott Children’s Hospital, 9Cardiac Surgery 
Department, University of Michigan, Ann Arbor, MI, 10Texas Children’s Hospital, 11Departments of Pediatrics, Baylor 
College of Medicine, Houston, TX, 12Division of Pediatric Critical Care Medicine, Primary Children’s Medical Center, 
Salt Lake City, UT 
 
Abstract 
This paper focuses on understanding and analyzing patient care process variation in post-
operative care of congenital heart surgery. We aim to identify practice variance and the 
associated processes and/or factors that may offer opportunities for improving care delivery 
and clinical outcome. Focusing on five pediatric heart surgery sites, we have identified and 
summarized numerous practice variations within the post-operative care process. 
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Specifically, from a system viewpoint, we pinpoint various process points along the post-
op care continuum in which difference in care coordination, management, resources and 
practice may lead to significant impact and reasons for the difference in LOS across the 
five sites.  
 Using clustering and machine learning approaches, we rank the significance of 
these factors in predicting and influencing the length of stay of the patients. In particular, 
ICU care, step-down care, and early extubation offer the highest potential of returns. The 
strength of this study is that by combining direct observations and data collecting, 
interviews, system process map design, system simulation, and machine learning together, 
we can identify and prioritize major practice variance and key factors that may influence 
clinical outcome. The findings can be readily presented in a systematic manner to the 
hospitals for potential process improvement.  As a result of this study, a collaborative 
learning study has been started with a new clinical practice guideline (CPG) established 
for early extubation for a selected group of patients. A clinical trial involving these five 
sites, using the new CPG, began in April 2014, A clinical paper is currently in preparation 




Numerous studies have shown that surgical outcomes differ among congenital heart centers. 
One possible reason for these differences is that the current healthcare environment is 
characterized by substantial practice variation – some of which have negative 
consequences in the delivery of recommended care[2-7]. Due to the innate variation in 
patient symptoms, patient diseases, provider training, provider experience, health system 
design, and resource allocation, variation cannot be completely removed in healthcare[73-
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76]. However, understanding the causes and effects of variation can help providers and 
healthcare organizations avoid practices that negatively impact outcomes. 
 
 Practice variance is the difference in care between two similarly diagnosed patients 
that causes difference in length of stay (LOS) in the hospitals. Practice variance leads to 
variations in care quality, inefficient use of resources, fewer patients being treated, 
increased costs for both patient and hospitals, poor hospital utilization and increased patient 
susceptibility. Practice variance is an important issue to analyze as a means to optimize 
care outcome and delivery.  
 
 In previous studies, various attempts to identify the nature of practice variation have 
been made. Studies have found associations between physicians[77, 78], geographic 
locations, and institutions[2, 79]. Furthermore, research suggests how to optimize 
appropriate level of practice variation with resource utilization[77, 80] and decision 
making processes[78]. Additional research suggests implementing practice guidelines to 
multi-clinical institutes improves standardized care and reduces highly variable results[81-
84]. Comparing resources, decision making and patient care between institutions might 
reveal the exact points of practice variance and help identify critical factors in reducing it, 
yet to date this has not been examined. 
 
 With this framework in mind, this paper aims to study patient care process variation, 
particularly from the provider standpoint in post-operative care of congenital heart surgery. 
In each hospital, physicians, nurses, and other hospital staff interact with each other and 
with patients in different ways. They also use resources differently. Specifically, we focus 
on four areas: 
1. Identify post-op care processes from each hospital and highlight practice variations 
on clinic and care management workflow. Because this study involves multiple 
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hospitals, we first focus on identifying overall post-op care processes in intensive care 
unit (ICU), cardiac step-down unit (CSU), patient hand-off from operating room (OR) 
to ICU, and patient hand-off ICU to CSU in each hospital. 
2. Understand practice variation among multiple hospitals and its contribution to 
different outcomes based on different resources, decision making process and care 
management style. Each hospital possesses different care resources; for example, a 
care team may consist of physicians, respiratory therapists, and registered nurses.  The 
care team makes different care decisions based on its resource availability. The 
variation often results in different care plans for similar conditions.  
3. Identify key factors that affect LOS using a computerized system model. Combining 
on-site observations with hospital data, a computerized system simulation model was 
designed. We analyze factors that may affect the total LOS in each hospital and 
categorize them as low, medium and high. Using the categorization, we demonstrate 
how the LOS may be improved through changes in clinical practice. 
4. Identify standardized processes in each hospital’s protocols and compare the variation 
among them. Some hospitals follow strict institutional protocols in managing patient 
care, while others employ flexible processes based on experience. As care process 
becomes more complex and involves different levels of providers, communication and 
role definition becomes more important. We study the existence of institutional 




Our study team, comprised of a pediatric cardiologist, a cardiac intensivist, a cardiac 
surgeon and a group of system engineers, completed week-long site visits to five pediatric 
heart centers, Children’s Healthcare of Atlanta, Children’s Healthcare of Philadelphia, C.S. 
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Mott Children’s Hospital, Texas Children’s Hospital and Primary Children’s Hospital in 
Utah in 2012 and 2013. 
 
Process and Workflow Observation and Data Collection 
The site visits focused on observation and data collection of the entire operative and post-
operative care process. Each site conducted their clinical tasks as usual and allowed the 
study team complete access to all events. We observed and recorded data and information 
in OR process, hand-off from OR to ICU, care team resources and staffing in ICU, ICU 
rounds, ICU care process, chest closure in ICU, chest tubes removal in ICU, extubation in 
ICU,  hand-off from ICU to CSU, and discharge coordination and family education in each 
hospital. The observations focused on key factors including: 1) process and outcomes, 2) 
personnel and resource availability, and 3) decision making process. We captured activities 
from various personnel across the entire care continuum. Resource availability includes 
team composition, numbers of care members and skill set, staff shift and hours of care, and 
resource coordination and support for patient care. Decision making was noted throughout 
the post-op care process, including decisions pertaining to daily rounding, medications, 
sedations, laboratory test, x-ray, chest closure, tube removal, extubation, hand off from 
ICU to CSU, and discharge process. 
 
Direct Interviews 
We interviewed key personnel in four main areas:  the patient-care team in ICU, the 
surgical team; the CSU and discharge team; and the administrative leaders. Specifically, 
the ICU personnel includes the attending and fellow physician in the care team, nurse 
practitioner, respiratory therapist, pharmacist, nutritionist, charge nurse and registered 
nurse in ICU. The surgical team covers the attending and fellow surgeon, attending and 
fellow anesthesiologist, nurse practitioner, charge nurse, registered nurse, and physician 
assistant.  The CSU and discharge team personnel include attending physician, charge 
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nurse, registered nurse, social worker, and child life specialist if available.  The 
administration leaders consists of chief of cardiology, directors of ICU and CSU, chief of 
surgical team, head of nurse, director of research division, research physician and 
research nurse. The interviews focused on key factors similar to those mentioned above 
pertaining to the direct observation and data collection processes. These include process 
and outcomes, resource availability, and the decision making process, By design, the 
observations and interviews allow us to correlate the actual processes and tasks that occur 
versus the perceived steps that the personnel follow.  
 
Establish System Process Map 
A patient care system process map is next created to help understand and analyze the 
interplay of care and coordination. Specifically, the pathway for patient care is first mapped 
out, following a patient from hand off from OR to ICU until discharge in each site. After 
identifying the patient care steps, key personnel who are involved with each patient care 
step and the available resources that support the task are overlayed onto the system process 
map.  Next, decision making points and tasks are highlighted onto the system process map. 
Finally, we create an overall post-op care process common to all five sites from a systems 
viewpoint. Through the common system process map, variation points are captured and 






Figure 3- 1. A common post-operative process map for the five sites 
 
Computer Systems Model, Machine Learning and Simulation 
Combining observations and data from each hospital, we establish a computer system 
simulation model for further analysis. First we identify 7 major factors that influence LOS 
in each hospital:  
 Pre-Op: Before surgery, patients usually stay in ICU for a day to prepare for 
surgery. We set this stage as Pre-op. 
 Surgery: The length of surgery is between 2.5 hours to 6 hours.  
 Extubation: Extubation may be performed in the OR after surgery. However, some 
patients may spend recovery time in the ICU and extubation is then performed in 
the ICU. 
 Tube removal: This factor links to surgical care in the ICU. The surgical team may 
be involved in making the decision of removing the tubes and closing the chest. 
This step is complex and varied across the sites.  
 ICU care: Patients recover in the ICU after surgery. The ICU care team takes care 
of the patients with care plan updated every day. Based on our observations, each 
hospital has a different approach in the creation of  patient care plans. 
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 Discharge planning: Each hospital has its own family education plan and checklist. 
We focus on when and where each hospital begins the discharge and education 
plans. 
 Step-down care: Patients move to step-down area for recovery. Step-down care is 
less intensive, nonetheless patients may spend extensive time in the step-down area. 
 
To scope the study, the team decided to focus on two procedures: Tetralogy of Fallot (TOF) 
complete repair such as VSD (Ventricular septal defect) and ASD (atrial septal defect); and 
Coarctation of the Aorta (specifically < 12 month of age).  Each center operates roughly 
25 ~ 40 of these procedures   per year.  Variables are assigned the following distributions 
based on observations and discussions. Uniformly across each site, Pre-op takes 
approximately one day. Table 3-1 summarizes the distributions used for each of the factors 
at each site. “Tri” means triangular distribution and “N” means normal distribution. We 
caution that within the system simulation model, each entity is characterized not only by 
the service distribution; rather, the characteristics of the process, interplay of providers and 
processes and patients are all captured and simulated. 
 





To understand the LOS correlation across the five sites, we first perform an expectation–
maximization (EM) clustering algorithm on the surgical cases to categorize the LOS into 
related groups. Machine learning is then performed to pinpoint the key factors that are most 
predictive of the LOS. Based on the machine-learning results, we synthesize potential 
clinical strategy to reduce LOS. Simulation is then performed to analyze the potential 
improvement over the current practice. 
 
3.1.3 Results and Findings 
 
Based on our site visits, we identified numerous points of process variation and ample 
opportunities for process improvement in post-op care. We summarize below some of our 
findings. 
 
ICU Care Process 
All five sites have similar care teams for post-op care in ICU. Basically, ICU patient care 
is provided by two teams, each consisting of an attending physician, along with one or two 
fellows to cover the daytime shift. There are some variations.  First, site 4 is unique in its 
care team formation compared to the other sites. Namely sites 1, 2, 3, and 5 have two teams 
in ICU with each team covering half of the ICU patients, while site 4 has one team 
consisting of two attendings and three to four fellows covering all ICU patients. 
 
Table 3- 2. Number of beds at each of the five sites 
 Site 1 Site 2 Site 3 Site 4 Site 5 










At site 2, only physicians perform morning rounds, whereas a pharmacist and a 
nutritionist participate along with physicians in the other four sites. In addition, site 2 care 
team takes much longer time at each bedside because the team performs medical actions 
such as extubation and ordering of medications during the morning rounds while the other 
four sites perform medical actions only after rounds are completed.  
 
 At sites 2 and 5, night shift patient care is covered by an attending and a fellow, 
whereas at the other 3 sites, only a fellow is present to cover the ICU night shift, attendings 
are available on call.  As a result, various medical actions are made during the night shifts 
at sites 2 and 5; while the other 3 sites generally perform these medical actions in early 
morning when attendings are present.  
 
 Finally, only sites 2 and 5 perform collaborative joint rounds with specialists from 
other divisions for patients with complex disease.  They join the ICU care team in the 
morning walking rounds, and discuss with the ICU team on the patient care plan every day. 
Table 3-3 summarizes practice variations across the ICU care process among the five sites. 
 
 
Table 3- 3. Summary of practice variations in ICU care process 
 Site 1 Site 2 Site 3 Site 4 Site 5 
Care team 
Daytime shift 
2 teams: each 
with 1 
Attending 









2 teams: each 
with 1 
Attending 
2 Fellows or 
1 Fellow + NP 
Pharmacist 
Nutritionist 
1 team with 2 
Attendings 
3 to 4 fellows 
Pharmacist 
Nutritionist 













1 Fellow + NP 
with attending 
on call 












No Yes No No Yes 
Average time 
per patient 
7 to 9 minutes 30 minutes 10 minutes 7 minutes 6 to 10 minute 
 
Decision Making and Coordination 
In daily post-op care, there is practice variation on patient care coordination and decision 
making processes. Each site has a different policy on a collaborative meeting between ICU 
team and surgical team. Sites 4 and 5 hold a joint meeting that includes both the ICU and 
the surgical teams every morning; while weekly meeting and seminar are observed at sites 
1, 2, and 3. As a result, the surgical teams in sites 4 and 5 make decision on patient care 
plan and / or they are actively engaged in  surgical action such as chest closure and chest 
tube removal; whereas such decisions usually are  made by the ICU team at sites 1, 2, and 
3. A surgical team member, usually a fellow surgeon, performs chest closure at sites 3 and 
5; while ICU attending and fellow perform such a surgical care at sites 1, 2, and 4.  
 
Additionally, decisions made during rounds show some variation. All sites except 
site 3 update patient care plans such as medications, ventilation setting, extubation schedule 
and feeding on a daily basis while the care team conducts walking rounds. On the other 
hand, site 3 handles the patient care plan very conservatively, it updates care plan after the 
ICU attending call.  
 
For hand off, all sites employ a team-to-team approach. However, site 1 process is 
less structured than the other four sites.  Typically, an attending anesthesiologist and a 
fellow surgeon and other OR staff move patients to ICU. However, only ICU attending and 
attending anesthesiologist are present during hand-off at site 1 while anesthesiologist and 
49 
 
fellow surgeon report patient information to the ICU team during hand-off at the other four 
sites. 
 
For shift change, sites 3 and 5 change shift as team to team through the evening 
round, both daytime and night shift team members attend rounds and share information 
about the patients. Sites 1, 2, and 4 change shift via a process approach. Night shift team 
conducts the evening rounds without daytime shift team because they share information 
before evening rounds in a person-to-person meeting. 
 
Except site 3, decision making of early extubation in the OR or extubation in the 
ICU within an hour after hand-off is made by attending anesthesiologist during the 
operation. In particular, site 2 and 4 are more proactively engaged in early extubation than 
the other sites. Meanwhile, site 3 does not perform early extubation in the OR. For 
extubation in the ICU, the attending physician decides when to extubate across all five sites, 
but the actual extubation is carried out with some difference. Attending physician generally 
performs extubation at sites 2 and 5 while one of the available personnel among attending, 
fellow, NP and RT performs extubation at the other sites.  
 
Table 3-4 summarizes the practice variance on decision making and care 
coordination. It includes also comparisons on x-ray order, laboratory test order, sedation 
and feeding guideline. 
 
Table 3- 4. Summary of practice variance in decision making and care coordination 






Weekly Weekly Weekly Daily Daily 
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ICU team ICU team ICU team 






ICU team ICU team 
Surgical 
team 











Daily base Daily base 
Hand off 







OR team to 
ICU team 
OR team to 
ICU team 
OR team to 
ICU team 






One to one 
Process 
approach 





One to one 


































X-ray order Request basis Request basis Daily basis Request basis Request basis 






Avoid Generous Avoid 
Attending’s 
call 





Discharge Plan, Family Education and Protocols 
Each hospital has a different approach for discharge and family education. Discharge plan 
begins in the ICU at sites 1, 2, 5; whereas it begins in the CSU for sites 3 and 4. All five 
sites provide medication and recovery education to family in the ICU; but most sites 
provide training in the CSU except site 2. Site 2 begins all family education in the ICU. 




Table 3- 5. Contrast of practice variations in discharge, family education and protocols 
 Site 1 Site 2 Site 3 Site 4 Site 5 
Discharge 
plan 
ICU ICU CSU CSU ICU 
Family 
education 
Mostly CSU ICU Mostly CSU Mostly CSU Mostly CSU 
Patient care 
protocols 
Yes No No No 
Yes, but does 






Yes, but just 
reference 
Yes 



























Figure 3- 2. Practice variance at each hospital 
 
We highlight the following variance among the five sites on the process map. 
 Hand-off from OR to ICU communications: Site 1 uses one-to-one communication 
between OR attending anesthesiologist and ICU attending physician, while the 
other 4 sites use team-to-team communication. 
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 Surgical decision in ICU: In Sites 4 and 5, surgical team makes surgical care plans 
in ICU such as chest closure and tube removal, while ICU team makes the plans 
in the other 3 sites. 
 Surgical performer in ICU: Interestingly, the surgical team performs chest closure 
and tube removal in site 2 and 5, while the ICU team performs the care in the other 
3 sites. 
 Early extubation policy: Site 3 does not have an early extubation policy, while the 
other 4 sites all have it. 
 ICU care plan: At site 3, ICU team approaches daily care plan very conservatively, 
sometime completely depending on ICU attending’s call. While the other 4 sites 
update the plan aggressively. 
 Extubation in ICU: ICU attending physicians mainly perform the extubation at 
sites 2 and 5, while available staff such as fellow physician, nurse practitioner or 
respiratory therapist can perform the extubation based on attending’s call in the 
other 3 sites. 
 Family education: Family education begins at ICU in site 2, while it begins at CSU 
in other 4 sites. 
 Discharge plan: Discharge plan begins at ICU at sites 1, 2 and 5, while it begins 
at CSU at sites 3 and 4.  
 
Lastly, we observed a difference in process order among the 5 sites. In Figure 3-3, we 





Figure 3- 3. Process order in each hospital 
 
EM Clustering, Machine Learning and Simulation 
EM clustering performed on the surgical cases of the five sites yield three distinct clusters 
based on the LOS: Short: LOS  <  6.7, Medium: 6.7 < LOS  <  8.8, Long: LOS > 8.8 (Figure 
3-4). The distribution is roughly 31.2%, 26.7%, and 42.0% respectively.  
 
 
Figure 3- 4. Clusters of LOS from the five sites 
 
We select randomly 66% of these surgical cases and perform supervised learning 
on them using 24 different types of classifiers, including DAMIP[79, 85], logistic model 
decision tree, random forest, support vector machine, naive Bayesian, k-nearest neighbors, 
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and Bayesian network. The remaining 34% of surgical cases are used for blind prediction. 
DAMIP performs the best with 95% 10-fold cross-validation unbiased estimate, and over 
90% on blind prediction accuracy for each of the 3 groups. Bayesian network also returns 
excellent results with 92.8% 10-fold cross-validation unbiased estimate, and over 85% 
blind prediction accuracy for each of the groups. All other classifiers suffer from 
imbalanced data and score unevenly in one of the group prediction.  
 
Running feature selections on the 7 major factors on all the classifiers, we select 
the top 50 percent of all the models and calculate the Gini Importance on the features to 
determine their significance in predicting/influencing the LOS. Table 3-6 shows that ICU, 
step-down, and early extubation are the top three features. ICU and step-down care are 
complicated factors as they involve multiple resources, staffing, medication and care 
coordination, and scheduling among various units in the hospital. Meanwhile, extubation 
is a process that the hospital can conveniently adopt a new protocol and measure its impacts 
on LOS. Furthermore, extubation can affect time it takes for tube removal and ICU care 
management simultaneously, and will have a downstream effect on step-down care also. 
 
Table 3- 6. The Gini Importance score for each of the factors in predicting the LOS 
Factor Extubation Tube Removal ICU care Stepdown care Discharge Plan 
Total Gini 
Importance Score 
82 72 89 93 70 
 
We first run the computer system simulation model using the 7 major factors 
collected from field observations and the parameters in Table 1 to arrive at the expected 
LOS of each hospital.  Next, we simulate early extubation to estimate the expected 
improvement in LOS.  Figure 3-5 contrasts the results. In particular, “simulation 
observations” reports the simulation results of the current LOS based on our field 
observations, while “simulation early extubation” reports the anticipated LOS when early 
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extubation is implemented at each site. We find significant reduction in LOS, ranging from 
10.0% to 30.0%.  This may have significant impact on the health and cognitive 
development of the patients. 
 
 




This paper focuses on understanding and analyzing patient care process variation in post-
operative care of congenital heart surgery. We aim to identify practice variance and the 
associated processes and/or factors that may offer opportunities for improving care delivery 
and clinical outcome. Focusing on five pediatric heart surgery sites, we have identified and 
summarized numerous practice variations within the post-operative care process. 
Specifically, from a system viewpoint, we pinpoint various process points along the post-
op care continuum in which difference in care coordination, management, resources and 
1 2 3 4 5
Tetralogy of Fallot (complete
repair)
7 5 11 14 6
Coarctation the aorta repair 8 4 7 11 4.5
Simulation: observations 7.8 5.68 12.26 11.2 6.69




Tetralogy of Fallot (complete repair) Coarctation the aorta repair
Simulation: observations Simulation: Early extubation
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practice may lead to significant impact and reasons for the difference in LOS across the 
five sites.  
 
Using clustering and machine learning approaches, we rank the significance of 
these factors in predicting and influencing the length of stay of the patients. In particular, 
ICU care, step-down care, and early extubation offer the highest potential of returns. The 
strength of this study is that by combining direct observations and data collecting, 
interviews, system process map design, system simulation, and machine learning together, 
we can identify and prioritize major practice variance and key factors that may influence 
clinical outcome. The findings can be readily presented in a systematic manner to the 
hospitals for potential process improvement.  
 
Although analysis of multi-institutional information might provide insight about 
such practice variation, the process is time-consuming and study design is not trivial. It is 
difficult to capture critical factors that may enhance patient care such as decision-making 
processes, information transfer, and the use of protocols.  
 
Each site may apply our findings to identify its own weakness and potential 
improvement of its current process. The findings may assist clinicians in developing 
clinical practice guidelines and protocols for improving LOS and treatment outcome. 
While LOS is only one measure of outcome, it may have significant impact.  
 
Beyond individual site improvement, this work facilitates collaborative learning 
across the multi-institutional sites. ICU and step-down care are complicated factors as they 
involve multiple resources, staffing, medication and care coordination, and scheduling 




Because changes in ICU and stepdown care can be complex and involve multiple 
staff, and process change and care coordination and scheduling involving numerous units 
at multiple timeline within the care process, early extubation offers a unique opportunity 
for collaborative learning. Multi-site testing of a change process is important for clinical 
improvement and in validating effects from change in clinical practice when the number 
of surgical cases at each site is not high. At the time of this writing, a collaborative learning 
study has been started with a new clinical practice guideline (CPG) established for early 
extubation for a selected group of patients. A clinical trial involving these five sites, using 
the new CPG, began in April 2014. A clinical paper is currently in preparation to discuss 
the design of the collaborative study and the establishment of the CPG protocol.   
 
The findings in this study allow us to better understand patient workflow and care 
processes for pediatric heart patients. Besides early extubation, we will explore areas of 
potential improvement based on our findings. In particular, we will identify actionable 
changes that can be tested to understand the impact on LOS and the clinical outcome for 
the patients. Such work requires careful design of CPG and implementation protocol, and 
clinical trials must be carried out to understand potential impacts and effects. 
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3.2 Investigating a Needle-Based Epidural Procedure in Obstetric Anesthesia 
This section consists of the entire paper, “Investigating a Needle-Based Epidural Procedure 
in Obstetric Anesthesia” that has been submitted to Anesthesiology. 
 
Investigating a Needle-Based Epidural Procedure in Obstetric Anesthesia 
 
Eva K Lee, PhD1,2,3,, Haozheng Tian, MS1,2,3, Jinha Lee, MS1,2,3, Xin Wei, MS1,2,3,  
John Neeld, Jr., MD4, K Doug Smith, MD4, Alan R Kaplan, MD4 
1NSF-Whitaker Center for Operations Research in Medicine and HealthCare; 2NSF I/UCRC Center for Health 
Organization Transformation; 3School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, 
GA. Northside Hospital Department of Anesthesia, Atlanta, GA 
Abstract  
This paper reports the findings of an investigation into the safety and efficacy of a new 
large-dose, needle-based epidural technique in obstetric anesthesia. The new technique 
differs from a traditional, catheter-based approach in that the anesthetic dose is 
administered through an epidural needle prior to insertion of the epidural catheter.  
Two cohorts of subjects supplied data: the first composed of 750 patients permitted 
modeling and predictive analysis; the second that included 1,398 randomly selected 
patients provided independent validation. 
The study revealed that, compared with a catheter-based approach, a needle-based 
approach is faster (mean 15.63minutes versus 20.00 minutes) and more dose-effective 
(mean 24.99 ml versus 30.27 ml) in achieving comparable sensory levels. The study also 
showed that injecting large doses (up to 20 ml) in the epidural space through the epidural 
needle is safe, followed usually by good outcomes for patients; any associated 
complications were similar to those reported in published literature. Further, we found that 
if the needle dose is kept under 18 ml the resulting hypotension rate ordinarily will be 
significantly lower (mean 21%). 
Using advanced analytics, we developed a machine learning framework that can predict 
the incidence of hypotension with 85% accuracy. The discriminatory features uncovered 
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include weeks of pregnancy, patient allergies, number of epidural replacements, epidural 
needle/catheter dose, number of epidural reboluses and dosage).   
The findings from this investigation should facilitate delivery improvement as well as help 




The potential consequences of failed or misplaced epidural needles are well known to 
obstetric anesthesiologists. A well-documented epidural complication, a “wet tap,” results 
in a headache and possible total spinal, requiring immediate maintenance of the patient’s 
airway and blood pressure. The inadvertent intravenous injection of local anesthetic into a 
vein in the epidural space leads to seizures and fatal cardiac arrhythmias. Equally 
worrisome is the inadequate epidural block leading to complications during a caesarian 
section. These complications include an emergency general anesthetic, resulting in airway 
loss, hypoxemia, hypercarbia and death[86-88]. However, to date, limited research has 
been performed regarding standardization of the epidural analgesia procedure to avoid 
practice variance with minimal complications. Furthermore, little is known regarding 
practice and patient outcome related to large doses of local anesthetic injected through the 
epidural needle. 
 
In this paper, we perform an in-depth study of epidural process to capture practice 
variance and to quantify the time and dose required to achieve the desired sensory level. In 
particular, we establish a safe and quickly effective epidural dose that can be administered 
through the epidural needle prior to the insertion of the epidural catheter. Based on clinical 
results, we quantify complications for doses as large as 20 ml that is injected through the 
epidural needle. We contrast the proficiency of physician practice and provide insights on 
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their preference in medication and dosage. Understanding the causes and effects of such 
variation can help providers and healthcare organizations avoid practices that negatively 
impact outcomes. Using machine learning approach, our study reveals practice 
characteristics that result in the best outcome with least complications. Our findings 
facilitate establishment of new clinical practice guidelines (CPG) for care outcome and 
delivery improvement. 
 
3.2.2 Materials and Methods 
 
This study aims to capture practice variance, quantify dose-sensory achievement 
characteristics, and evaluate the safety and utility of injecting large doses (up to 20 ml) in 
the epidural space through the epidural needle for elective caesarian sections in the hands 
of experienced anesthesiologists at a large urban obstetric hospital.  The study involves six 
major steps. 
 
1. Develop process mapping of patient and epidural service workflow via objective 
process observations and structured interviews. 
2. Perform time-motion studies of epidural processes, record complications and practice 
variance, and analyze hospital data. 
3. Perform statistical analysis of collected data, conduct system analysis on practice 
variance, quantify effective dose-sensory level achievement, and develop a machine-
learning predictive analytic to predict patient/outcome characteristics.   
4. Develop a computerized simulation-optimization system to simulate current 
performance, optimize systems and estimate anticipated global improvement. 
5. Report findings and determine practice guideline recommendations for improved 





Figure 3- 6. The study schema and interdependencies of the analytic framework 
 
 
Epidural Workflow and Services 
Figure 3-7 summarizes the epidural process performed by anesthesiologists. We observe 
variation in the processes (green). Anesthesiologists choose one of three basic techniques 
(or a combination thereof) in order to correctly identify the epidural space via the technique 
of loss of resistance: air, saline and local anesthetic. Medication dosages vary by provider 
with the majority of them injecting as much as 20 ml’s through the epidural needle prior to 





Figure 3- 7. Anesthesiologist epidural procedure workflow process. Green highlights 
processes with variance among providers 
 
Observations, Time-Motion Studies, and Chart Review 
From January 2014 through December 2014, eight trained observers collected epidural 
process data via a standardized checklist through shadowing the epidural team. Data 
collection included patient demographics, vital signs, medication type and dosage, time to 
achieve sensory level, outcomes and response to medication. The observers simultaneously 
conducted time-motion studies, measuring service time for each step of the epidural 
workflow. Variability of practitioners and processes were also captured. Along with 
observation, a random sampling of charts was reviewed to serve as a validation set for our 
machine learning and system simulation-optimization analysis.  
 
Two types of epidural approaches were defined based upon the primary delivery 
mechanism of the majority dose. If the majority of the dose is delivered through a needle, 
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it is defined as a needle-based approach. Likewise, a catheter-based approach delivers the 
primary dose through a catheter. 
 
Statistical Analysis 
Statistical analysis was conducted to quantify variations and their associated outcome. 
Specifically, variations on delivery types, complications caused by delivery types, time to 
sensory level, medications and dosage, epidural approaches (needle-based and catheter-
based), and practitioners’ performance were noted.  
 
Statistical analyses were performed using MATLAB[89]. Statistical significance 
was assessed at the 0.05 level unless otherwise noted. Descriptive statistics were calculated 
for all variables of interest and included: median and 25th to 75th percentiles, and counts 
and percentages, when appropriate. Two-sample t-test and Wilcoxon rank-sum tests were 
used to compare continuous variables between groups and Chi-square tests were used for 
comparing categorical variables between groups. 
 
Next, a machine learning predictive framework was designed to uncover key 
factors influencing and predicting hypotension. Specifically, we used discriminant analysis 
via mixed integer program (DAMIP) as our classifier[85, 90] and contrasted it with other 
popular classification methods. 
 
Machine-Learning Predictive Analytic Framework: Discriminant Analysis via Mixed 
Integer Program (DAMIP) 
Suppose we have 𝑛 entities from 𝐾 groups with 𝑚 features. Let  be the 
group index set,  be the entity index set, and  be the 
feature index set.  Also, let 𝓞𝑘,  and , be the entity set which belong to group 
𝑘.  Moreover, let 𝓕𝑗, , be the domain of feature j, which could be the space of real, 
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integer, or binary values.  The 𝑖 th entity, , is represented as 
, where 𝑦𝑖 is the group to which entity 𝑖 
belongs, and  is the feature vector of entity 𝑖.  The classification model finds 
a function  to classify entities into groups based on a selected set 
of features. 
 
Let ?𝑘  be the prior probability of group 𝑘 and 𝑓𝑘(𝒙) be the conditional probability 
density function for the entity   of group 𝑘 , .  Also let , 
be the upperbound for the misclassification percentage that group h 
entities are misclassified into group 𝑘.  DAMIP seeks a partition  of ℝ𝐾 , 
where 𝑃𝑘 , , is the region for group 𝑘, and 𝑃0 is the reserved judgement region with  
entities for which group assignment are reserved (for potential further exploration).  
 
Let 𝑢𝑘𝑖 be the binary variable to denote if entity 𝑖 is classified to group 𝑘 or not. 


































DAMIP has many appealing characteristics including: 1) the resulting classification 
rule is strongly universally consistent, given that the Bayes optimal rule for classification 
is known[94, 95], 2) the misclassification rates using the DAMIP method are consistently 
lower than other classification approaches in both simulated data and real-world data; 3) 
the classification rules from DAMIP appear to be insensitive to the specification of prior 
probabilities, yet capable of reducing misclassification rates when the number of training 
entities from each group is different; 4) the DAMIP model generates stable classification 
rules on imbalanced data, regardless of the proportions of training entities from each 
group[90, 94, 96]. 
 
The entities in this study correspond to the patients. The features are patient 
demographics, health conditions and clinical history, epidural workflow (processes, 
medication, and dosage), and provider experience and delivery characteristics. The goal is 
to undercover discriminatory features that can predict which patients will have a higher 
likelihood for complications. Identifying these patients will allow practitioners the chance 
of intervening with the intention of reducing complications. It also facilitates development 
of new CPGs for improved clinical outcome. 
 
In supervised learning, each subject’s status in the training set is known. The 
training data are input into the DAMIP machine-learning framework. Ten-fold cross-
validation is performed on the training set to obtain an unbiased estimate. 
 
In 10-fold cross-validation, the training set is randomly partitioned into 10 roughly 
equal subsets. Of the 10 subsets, 9 subsets are used as training data, and the remaining 1 
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subset is retained as the validation data for testing the rule. The cross-validation process is 
then repeated 10 times (the folds), with each of the 10 subsets used exactly once as the 
validation data. The 10 results from the folds are then summed to produce an unbiased 
estimation. The advantage of this method over repeated random subsampling is that all 
entities are used for both training and validation, with each entity used exactly once for 
validation.  
 
To gauge the predictive power of the rule, we perform blind prediction on an 
independent set of subjects; that is, these individuals have never been used in the learning 
process. We run each subject through the rule, which returns a status. This status is checked 
against the individual's actual status. Hence, we always compare our prediction with the 
actual outcome in measuring predictive accuracy. 
 
Lee et al.[91] (2003), Lee[85] (2007a), Lee and Wu[92] (2009), Brooks and Lee[94] 
(2010), and Brooks and Lee[95] (2014) detail the DAMIP modeling and its theoretical and 
computational contributions. Note that mathematically DAMIP is proven to be NP-
complete[94, 95]. We solved the instances for this epidural study using advances in 
hypergraphic theory[97]. 
 
Development of a Computerized Simulation-Optimization System 
A computer simulation-optimization model was established as a framework for modeling 
and optimizing the entire epidural workflow. This allows for development of improved 
CPGs.  
 
Parameters in the simulation include the entire epidural workflow as shown in 
Figure 2. The model captures delivery characteristics, service time, types and probabilities 
for each provider; response, risk factors, and outcome characteristics (including 
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complication) of each patient; and overall throughput of processes. The model was fitted 
using the data collected from our time-motion studies and observations to simulate the 
annual hospital patient visits and treatment performance. The computer simulation model 
captures practice variations statistically, and allows us to investigate improvement 
strategies. We first fine-tuned the model to reflect the hospital regular performance. Then 
using the validation set from chart review, we further fine-tuned and cross-validate the 




Northside Hospital delivers the highest number of newborns in the United States (the 
Centers for Medicare & Medicaid Services). During the study period, 19,651 deliveries 
were performed with 55.3% vaginal birth and 44.7% C-section. Among these, 75.1% 
received epidural analgesia. A total 750 parturition cases under routine epidural analgesia 
were observed in full detail. This includes 667 C-section, 76 vaginal birth, and 7 unlabeled 
cases. Majority of them (94%) were performed with patients in the sitting position. The 
observations cover 44 anesthesiologists.  
 
The two groups of patients have similar distributions in weight (p < 0.3138), height 
(p < 0.5784), and weeks of pregnancy (p < 0.3082). The occurrence of allergies is similar 
(C-section group: 13.75%, vaginal birth group: 16.44%). 73.04% of the C-section patients 
have had previous deliveries. And, 29.41% of the vaginal deliveries are primigravidas. The 
systolic blood pressure of C-section and vaginal birth patients is similar (p < 0.5700). 
However, the diastolic pressure of vaginal birth patients (73.0714 mmHg) is lower than 




The independent set of patients used for validation of findings consists of 1,398 
cases obtained through chart review. This includes 892 C-section, 505 vaginal births, and 
1 unlabeled case. This represents 10% of the newborns between January to September 2015. 
 
C-section versus Vaginal Birth 
Table 3-7 compares vaginal birth and C-section by age, type of medication and dosage, 
time to achieve desired sensory level, achieved sensory level, and outcomes. 
 
Age: It is well-documented that advancing maternal aged women are more likely to have 
cesarean delivery without labor[98]. The hospital data echoed this trend. The average age 
for the C-section group was 32.72 versus 30.77 of the vaginal birth group (p-value < 
0.0089). 
 
Medication: More than 40 combinations of medication are used. Table 3-7 shows the most 
commonly used drug combinations. Ropivacaine is used for vaginal birth patients since 
Ropivacaine is less lipophilic than bupivacaine and less likely to penetrate large myelinated 
motor fibers, resulting in a relatively reduced motor blockade. It is preferred in vaginal 
birth where motor blockage is undesirable[99]. 
 
Sensory level achievement: Sensory level is an important indicator to measure the effect of 
anesthesia. A higher than desired anesthesia level (high block) can cause motor block, 
dyspnea, apnea and even loss of consciousness. Both groups achieve similar sensory level, 
with T4 and T6 being the most frequently achieved. However, the time it takes to achieve 
sensory level between the vaginal birth and the C-section groups is significantly different. 




Complications: Our observations identified six complication symptoms: hypotension, 
epidural replacement, wet tap, blood in the catheter/needle, high block, and nausea and 
vomiting. Only two symptoms of complications, hypotension and blood in the 
catheter/needle, were observed in the vaginal birth group. Since hypotension is the most 
common complication, we present detailed analysis on hypotension in a dedicated section. 
 
Table 3- 7. Variance between the vaginal birth and C-section patients 




Min 18 Min 17  
Q1 26 Q1 30  
Median 31 Median 33  
Q3 36 Q3 36  
Max 39 Max 49  
Mean 30.77 Mean 32.72 0.0089 

















































T2 0.00% T2 0.76%  
T3 0.00% T3 1.83% 
T4 61.02% T4 61.07% 
T5 11.86% T5 6.72% 
T6 23.73% T6 22.29% 
T7 0.00% T7 1.07% 
T8 0.00% T8 3.97% 
T9 0.00% T9 0.76% 
T10 1.69% T10 1.22% 
T11 0.00% T11 0.00% 




Table 3- 7. Continued 
Complications 
(Frequency) 





*Hypotension 11.84% *Hypotension 52.32% 
Blood in the 
catheter/needle 
2.63% 







Wet tap 0.15% 
High block 0.30% 
Nausea/Vomit 0.45% 
*Documented by physicians as hypotension based on their own criteria. 
 
Needle-based vs Catheter-based Approach 
We seek to quantify effective dose to achieve desired sensory level and evaluate the safety 
and utility of injecting large doses (up to 20 ml’s) in the epidural space through the epidural 
needle.  
 
Among the 750 observed cases, 717 cases (95.6%) were needle-based and 33 cases 
(4.4%) were catheter-based. Table 3-8 shows the dose distribution across the two 
approaches. In the needle-based approach, in almost all cases over 90% of the dose is 
delivered through the needle; whereas for the catheter-based approach, an average of 60% 
of dose is delivered via the catheter. 
 












Min (ml) 5 0 2 10 
Q1 (ml) 16 0 7.5 10 
Median (ml) 20 0 10 10 
Q3 (ml) 20 0 10 19.5 
Max (ml) 32 18 20 28 
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Table 3- 8. Continued 
Mean (ml) 18.66 1.42 9.70 13.97 
Mode (ml) 20 0 10 10 
 
Sensory level achievement: The average time to achieve similar sensory level (p < 0.7789) 
in needle-based approach was 15.63 minutes versus 20.00 minutes for catheter-based (p < 
0.0037, Figure 3-8). The time difference is significant for both vaginal birth and C-section 
deliveries (p < 0.0181, p < 0.0390 respectively, Figure 3-9). Hence, this study reports that 
needle-based approach in faster and effective in achieving the required sensory result.  
 
Furthermore, the needle-based approach uses less dose than catheter-based 
approach (mean 24.99 ml versus 30.27 ml, p < 6.0 e-05, Figure 3-10). These findings 
support that needle-based approach is more dose-effective, achieving faster and 
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Figure 3- 10. Needle-based vs Catheter-based: epidural dose used 
 
 






































General Statistics: Table 3-9 contrasts the hospital’s incidence of complications to 
published results[100-111]. Compared to published results, the complication incidence of 
needle-based approach appears to be comparable to traditional catheter-based approach. 
 





Nausea/Vomit Wet tap High Block 







































6.06% 0.00% 3.03% 0.00% 9.09% 3.03% 6.06% 
 
Hypotension: The most observed complications for spinal, epidural and combined spinal 
and epidural anesthesia (CSE), is hypotension. Depending upon different labor analgesia 
methods, hypotension rates reported by previous studies can be as high as 70%[112, 113]. 
Based on our practitioners’ definition of hypotension, the hypotension rate was 51.73% 
across all approaches and delivery types. It was 52.32% for C-section and 11.54% for 
vaginal birth. And the average age of hypotension group was 33 and non-hypotension 




We apply published hypotension definitions to our study and compare the 
hypotension rates in Table 3-10. Since all previously reported results except one involved 
very small sample sizes, we can only meaningfully compare the hypotension results based 
on the “30% Drop of mean arterial pressure (MAP)” definition. Table 3-10 reports first the 
complication statistics for the observed cases. In the reporting, we do not separate the 
needle-based versus catheter-based cases since statistically, there is no significant 
difference in resulting percentage of hypotension. To validate that the observed cases are 
representative of the overall hospital practice, we also report the complication statistics for 
the 1,398 charts reviewed. The study reveals that the needle-based approach requires less 
dose for faster and effective epidural analgesia without increasing the incidence of 
hypotension. 
 
Table 3- 10. Comparison of hypotension rates 
 
Percentage and sample 
size from literature 
Percentage and sample size in our study 



























16.3%[115] 17.04% 23.73% 21.62% 13.86% 23.54% 20.03% 
<90 mm 








































9%, n = 
53[120] 







16.40% 28.53% 24.72% 13.66% 29.48% 23.75% 
 
Uncovering Features for Predicting Hypotension 
Machine learning is employed to uncover clinical and patient features that can predict 
hypotension. This allows for potential clinical practice guideline modification and/or early 
provider intervention to mitigate the effect. Our study consists of three folds. First, we use 
561 observations from the first nine months (January – September 2014) and partition them 
randomly into two sets for training and blind prediction (as shown in Table 3-11). Next, 
we use the established predictive rules to blind predict the future three months of 189 
patients (October to December 2014). And finally we blind predict 1,398 patients from the 
period January to September 2015. This allows us to measure the accuracy in predicting 
status of future patients. It also sheds light on the consistency of the physicians’ 
hypotension definition. 
 
Table 3- 11. Distribution of patient cases randomly selected for training and for blind 
prediction 
 
*Hypotension No Hypotension Total 
Training set  
(observed cases from January – 
September 2014) 
206 218 424 
Blind Prediction  
(observed cases from Jan – Sep 2014)  
72 65 137 
Blind Prediction  
(observed cases from Oct – Dec 2014) 




Table 3- 11. Continued 
Total  
(observed cases for 2014)  
383 367 750 
Blind Prediction  
(chart review data from Jan – Aug 
2015) 
782 616 1398 
*Documented by physicians as hypotension based on their own criteria. 
 
Inputs to the computations consist of patient demographics, physical and allergy 
characteristics and overall health, weeks of pregnancy, number of redo epidurals, number 
of reboluses and dose, test dose, epidural needle/catheter dose, total dose, duration of 
injection, sensory level and time achieved, delivery type, position, medication type, and 
provider. Using the DAMIP machine learning algorithm, we seek to uncover a small subset 
of discriminatory features that can predict hypotension. DAMIP returns 27 predictive rules 
that result in greater than 82% 10-fold cross-validation and greater than 85% blind 
prediction for predicting hypotension and non-hypotension in patients for the period 
January – September 2014. The discriminatory features selected include weeks of 
pregnancy, number of redos, epidural needle/catheter dose, number of reboluses and 
dosage, and patients’ allergy. When blind predict against new patients from October – 
December 2014, the predictive accuracy reaches 89%. Further, it reaches > 85% when 
blind predicting patients from January – August 2015. Table 3-12 contrasts the 
performance of DAMIP against other well-known classifiers. Compared to other classifiers, 
we note the consistently good predictive accuracy of DAMIP in both hypotension and non-
hypotension patients.  
 
Identified provider practice features offer an opportunity for CPG improvement, 
whereas patient characteristics allow for special care intervention during epidural process. 
In the simulation study below, we use the identified predictive rules and their associated 
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discriminatory features to construct care / delivery redesign experiments in an attempt to 
reduce hypotension incidence. 
 
Table 3- 12. DAMIP classification results for predicting hypotension and comparison 
against other classifiers 
Classifier 
10-fold cross validation 
(424 cases) 
unbiased prediction estimate 
Blind Prediction on 137 
cases 
(January – September 2014) 
Blind Prediction on 189 
cases 



















65.60% 71.61% 51.76% 51.09% 73.85% 30.56% 59.79% 79.05% 35.71% 
Logistic 
Regression 
74.69% 88.24% 43.53% 47.45% 61.54% 34.72% 57.67% 67.62% 45.24% 
Naive Bayes 73.80% 87.47% 42.35% 43.07% 78.46% 11.11% 58.20% 89.52% 19.05% 
Random 
forest 










60.61% 68.29% 42.94% 49.64% 69.23% 31.94% 52.38% 72.38% 27.38% 
DAMIP 82.30% 82.50% 82.00% 89.00% 90.70% 87.50% 90.40% 89.20% 91.40% 
 
System Simulation and Clinical Practice Improvement 
We first ran the computer simulation model using parameters from the 750 observed cases. 
The simulation was run on 19,651 patients to approximate the total number of babies 
delivered during a calendar year. We focused on highly revealing issues based on outcome 
findings: re-do epidural procedure, hypotension and other complications such as blood in 
catheter/needle, wet tap, high block, and nausea and vomiting. Expected time for 
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completing the entire epidural workflow was 9.26 minute under current conditions. The 
first column in Table 3-14 shows the simulation results for one year. The resulting 
complication rates were compared to those of the 1,398 validated cases. Each complication 
is within 2-3% of its actual occurrence rate, indicating that the simulation reflects closely 
the hospital data.  
 
Guided by the results from machine learning and the identified discriminatory 
features, we optimize the needle-base epidural dose administration process and report 
briefly the anticipated changes from current practice on three scenarios. These scenarios 
focus on physicians’ variations on administering medication, test dosage and total dosage. 
Each scenario is characterized by the physician’s individual epidural technique. In our 
simulation model, each scenario reflects actual physicians’ characteristics such as selecting 
medications, loss of resistance technique and injecting durations. 
 




15-18 ml (Scenario 1) 
Needle dosage:  
20-25 ml (Scenario 2) 
Variable Dose Technique: 
 (Scenario 3) 
Test dosage 2 ~ 5 ml 0 ~ 5 ml 0 ~ 5 ml 
Epidural needle 
dose 
15 ~ 18 ml 20 ~ 25 ml 5 ~ 20 ml 
Total dosage 15 ~ 25 ml 20 ~ 30 ml 10 ~ 30 ml 
 
Scenario 1 reflects a moderate needle dose with a tight total dose across all 
practitioners (15-18 ml). Scenario 2 allows for higher needle dose up to 25 ml. Scenario 3 
offers broader dose variance reflecting current practice while limiting needle dose to 20 ml.  
Table 3-14 shows that Scenario 1 results in the lowest re-do rate, hypotension rate and total 
procedure time than the other two scenarios; whereas Scenario 3 shows acceptable results 
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on hypotension. Overall, all three scenarios improve the procedure time. Using high 
epidural needle dose, Scenario 2 performs worse than the current practice. For the 1,398 
chart review cases, the hypotension rate is 21% among patients satisfying Scenario 1 
criteria.  
 
Table 3- 14. Contrast of complication rates using 3 scenarios of needle-based approach 
Complication 
Occurrence rate 
per year: Current 
performance 
Scenario 1 Scenario 2 Scenario 3 
Re-do epidural process 
Needle 5.14% 
4.18% 4.75% 4.92% 
Catheter 5.15% 
Replace epidural 2.80% 2.40% 2.88% 3.02% 
*Hypotension 50.89% 31.82% 55.43% 49.47% 
Blood in catheter/needle 0.32% 0.31% 0.32% 0.33% 
Wet tap 0.17% 0.16% 0.18% 0.17% 
High block 0.33% 0.33% 0.33% 0.33% 
Nausea/Vomit 0.35% 0.34% 0.35% 0.35% 
Faint 0.17% 0.17% 0.16% 0.17% 
Procedure time 9.26 minutes 5.12 minutes 5.98 minutes 5.78 minutes 
*Based on definition of hospital providers. 
 
Practice Variance among Providers  
Forty-four physicians were observed. The years of practice ranges from 6 to 30 years. All 
physicians report using needle-based approach with over 68% acquired this skill at this 
hospital. 
  
The top five medications are used in over 50% of the patient cases. The most 
commonly used medication (Table 3-7) is chosen by every physician. Categorizing 
physicians by years of practice: greater than 25 years (long), between 10 to 25 years 
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(medium), and fewer than 10 years (short), reveals that physicians are consistent in the 
delivery dosage. There is no significant difference in their epidural dosage for C-section 
(long vs medium: p < 0.8590, short vs medium: p < 0.6623, long vs short: p < 0.8245). 
 
About 43.52% of providers favor the use of air in the loss of resistance technique 
(Figure 3-12, left). When comparing the time to sensory level versus different loss of 
resistance techniques, a significant difference is observed while the height, weight, and age 
of patients are similar across the preference techniques. When the loss of resistance utilizes 
air with local anesthetics, the average time to sensory level and frequency of re-bolus are 
lowest among all other techniques (Figure 3-12, right and Table 3-15). 
 
While there is marginal difference in epidural replaced rate, overall redo rate 
appears to be lowest among physicians with medium years of experience. This may be 
explained that they have adequate experience and knowledge and are in good physical 
condition to deliver high quality service. The statistics also show that experienced 
physicians have the lowest redo rate in loss of resistance (Figure 3-13).  
 
An online survey was used to capture physicians’ self-reported definition for 
hypotension. Table 3-16 reports the number of hypotension cases and physicians’ 
adherence to their own definition. “20% off baseline systolic” is the most common 
definition used by the providers; with 23 of them not only follow quantitative standard, but 










Table 3- 15. Frequency of re-bolus with different loss of resistance techniques 










Frequency of Re-bolus 27.66% 32.05% 17.74% 25.00% 37.50% 
 
Figure 3- 12. Loss of resistance techniques versus the time to achieve desired sensory 
level 




Table 3- 16. Self-report definition for hypotension and their observed compliance rates 
Hypotension definition No. of providers 
Average compliance rate 
with self-definition 
20% off baseline, systolic 15 110/168 
Below 90mmHg, systolic 8 24/72 
Below 90mmHg, systolic or 20% off base line, 
systolic 
4 27/44 
Below 100mmHg, systolic  
or 20% off baseline, systolic 
2 22/27 
Below 80mmHg, systolic  
or 20% off baseline, systolic 
1 3/3 
15% off baseline, MAP<55 1 4/9 
20% off baseline, MAP<55 1 13/17 
30% off baseline, systolic 1 3/10 
Total reported  33 206/350 
Not reported 11 N/A/33 




Of the 3,988,076 documented births in the United States in 2014, 32.2% were delivered 
via cesarean delivery; and among women delivering vaginally, as high as 61% received a 
neuraxial block. The potential consequences of a failed or misplaced epidural needle are 
well known to anesthesiologists who practice obstetric anesthesia. While much has been 
analyzed regarding complications, especially hypotension, there has been limited research 
regarding the dose-sensory response and standardization of the epidural analgesia 
procedure to reduce practice variance and maintain low rates of complication. Moreover, 
little is known regarding practice and patient outcome related to large dose injected through 




With increasing demand on quality of medical service and evidence of outcome, 
the medical providers seek to work collaboratively with systems engineers to 
comprehensively analyze the performance of the epidural anesthesia service. Specifically, 
we analyze and quantify the dose-sensory response evidence and the associated 
complications in the hands of experienced anesthesiologists. We also evaluate the safety 
of a needle-based epidural technique for elective caesarian sections and establish evidence 
of a safe-level of epidural needle dose. To the best of our knowledge, there is no previous 
comparative effectiveness study analyzing dosage delivered via needle versus catheter.  
 
The analysis involves two cohorts of pregnant women who received epidural 
analgesia procedure: 750 in 2014 and 1,398 in 2015.  First, the team shadowed the 
anesthesiologists and observed in-depth the epidural procedure for the 750 patients. The 
duration and dose required to achieve the desired sensory level and associated 
complications were captured. 
 
To establish the foundation for comparison, we first analyze the physical and 
medical background of these patients for the needle-based and catheter-based approaches. 
Our findings indicate that there is no significant difference among these patients in terms 
of weight, height, and weeks of pregnancy. But we did find that C-section patients are older 
than those women who choose natural birth. This is consistent with the national statistics. 
 
Among these 750 patients, the results show that needle-based approach is faster 
(15.63 minutes versus 20.00 minutes) and more dose-effective (requiring less dose, mean 
24.99 ml versus 30.27 ml) in achieving comparable sensory level than the traditional 
catheter-based approach. Our findings also reveal that injecting large doses (up to 20 ml) 
in the epidural space through the epidural needle is safe and results in good outcome for 
the patients. The associated complications (hypotension, epidural replaced, wet tap, blood 
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in the catheter/needle, high block, and nausea and vomiting) are similar to those reported 
in published literature. Further, if the needle dose is kept under 18 ml, the resulting 
hypotension rate will be significantly lower (60% reduction from 52.32% to 21%, using 
the hospital’s definition). 
 
Time to sensory level is an important measurement of quality of care. With shorter 
time and less dosage of medication to sensory level, mother and fetus also face less risk 
regarding complications, such as hypotension, nausea and fetal bradycardia. 
 
Using a DAMIP machine learning approach, we rank the significance of clinical, 
patient, and epidural procedural factors in affecting hypotension. In particular, we identify 
a small subset of discriminatory features, including weeks of pregnancy, patient allergies, 
number of redos, epidural needle/catheter dose, and number of reboluses and dosage that 
can predict hypotension with 85% confidence. 
 
The identified patient characteristics (weeks of pregnancy, allergies) allow for 
precautionary care intervention for at-risk patients during the epidural procedure. The 
provider practice features (epidural needle/catheter dose, number of redos, reboluses and 
dosage) offer an opportunity for clinical practice guideline development and process 
improvement. Using system simulation and optimization, we investigate scenarios to 
reduce the hypotension incidence. In particular, we focus on a CPG with three factors: test 
dose, needle dose, and the total dose of the epidural. Under this CPG, the hypotension rates 
can be driven down to 31% while the needle dose can be as high as 18 ml. 
 
A second cohort of 1,398 patients obtained via chart review is used to validate our 
findings to ensure that they are representative of the hospital clinical practice. We note that 
similar results are concluded in these patient cases, and that the DAMIP classification rule 
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can predict the hypotension of these patients with 85% accuracy. Further, under the needle-
dose of 18 ml, the hypotension complication rate is approximately 21%.  
 
We contrast the proficiency of physician practice and provide insights on their 
preference in medication and dosage. Understanding the causes and effects of variation can 
help providers and healthcare organizations avoid practices that negatively impact 
outcomes. Our results establish evidence of safe and effective epidural needle dosage. This 
facilitates evidence-based dose delivery to patients that results in safer and more effective 
pain control during child delivery. The new CPG results in fewer complications and helps 
with training of anesthesiologists based on evidence-based best practice.  
 
Injecting large doses through the epidural needle is not without risk. Only 
experienced anesthesiologists should attempt this technique. Even experienced 
anesthesiologists should be prepared to immediately treat total spinals with airway and 
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COMPUTATIONAL IN-SILICO DRUG DESIGN 
 
The drug discovery and drug development is long, costly and complex process[8]. 
Implementing new strategy in drug development requires practical process innovation to 
accelerate drug development. Here, theoretical and practical approach involves three major 
pieces 1) identifying critical processes in each phase on drug development, 2) building 
critical process model to accelerate drug development, and 3) suggesting possible scenarios 
to reduce cycle time from beginning to marketing in drug development. 
 
In this chapter, we describe the first in-silico drug design system model to accelerate drug 
discovery. Our model spans preclinical research, the IND review, clinical research, and the 
NDA review. We identify the global process for any drug discovery pathway with timeline 
along the entire system process. Next, we identify bottlenecks, and perform system 
optimization that offers a holistic view of discovery pathways. The integration of 
bottlenecks into possible candidate tasks which can be conducted simultaneously 
highlights critical paths for the accelerated development process. We define the critical 
paths as parallel model for the new drug development. Our generalized parallel model 
allows not only rapid development but also processes that minimize risk, cost, and time. 
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The drug discovery and drug development is long, costly and complex process[8]. The cost 
of drug development has risen markedly in the past 30 years [122-124]. The fully loaded 
cost to discover and develop a new drug is the highest it has ever been and is increasing 
exponentially[123]. Even the number of drugs approval rate have been marked as the 
lowest recently[125]. The time to discover and develop drugs is also significantly 
increasing. As a result, the pharmaceutical industry has been facing tremendous pressure, 
not only increasing R&D expenditure but also consequently rising health care cost in the 
society. Therefore, drug companies are under pressure to demonstrate that their products 
offer therapeutic or cost advantage over competitors’ products and non-pharmaceutical 
treatment options[124]. 
 
On the public sector’s standpoint, drug discovery and drug development has risen 
as important issue on several ways. First of all, serious outbreak of disease requires 
accelerated drug discovery and drug development. During nine months till the middle of 
December in 2014, more than 19,000 people were infected by Ebola virus and lots of the 
patients around 40% were dead by the Ebola virus disease(EVD). The outbreak through 
the year seems to keep increasing the number of cases and deaths unless efficient drugs or 
vaccines would not be provided. Since the first case of EVD was reported in March 2014, 
the outbreak has continued and the total number of 19,065 patients was reported as the 
confirmed or suspected in the EVD-affected countries, mostly happen in the three outbreak 
countries(Guinea, Liberia, and Sierra Leone)[126]. However, available therapeutics to treat 
the infected patients or vaccines to prevent people from infection is currently not developed 
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yet. Thus, saving stockpile of vaccines after quick process of development is considered as 
the most effective way to prepare the crises related to the biological agents such as EVD. 
Another issue on the drug discovery and drug development in the public sector is 
responding bioterrorism. After 9/11 terrorist attacks, additional attacks happened on 5 
October in 2001 using anthrax. The anthrax attacks revealed gaps in knowledge that 
compromise the ability to respond to a bioterrorist attack[127]. When the attacks happened, 
the appropriate antibiotic drugs to use and the duration of treatment remained uncertain. 
Therefore, immediate responses to the potential threats of bioterrorism attacks needs to be 
addressed.  
 
Several efforts to fulfill the needs of accelerated new drug discovery and drug 
development have been issued for a long time. Firstly, the Food and Drug 
Administration(FDA) has tried to expedite development and approval process with various 
attempts. The first program was “orphan drugs”, which helps a limited category of drugs 
to be provided to the market more efficiently in 1983[128]. After the first program, “fast 
track” was introduced in 1988 as a second program to expedite the development and 
evaluation process of new drugs for serious or life-threatening diseases[128]. In 1992, the 
“accelerated approval” pathway was created to accelerate approval of particular 
investigational drugs, allowing approval based on surrogate endpoints in place of clinical 
endpoints. Also, “priority review” program was initiated in 1992, to expedite FDA review 
of a completed new drug application(NDA)[128]. In 2012, Congress created the 
“breakthrough therapy” designation, which may be based on surrogate endpoints, receive 
greater FDA resources to expedite their development and approval. However, these 
expedited drug development and FDA programs lead some possible disadvantages such as 
drug safety concerns, insufficient or delayed studies to confirm preliminary evidence, 
potential industry capture associated with the fees paid for expedited review, and public 
misperception of the therapeutic value of drugs approved via expedited pathways.  
89 
 
Secondly, in 2004, the FDA has developed the Critical Path Initiative(CPI), a 
project that is intended to improve the drug and medical device development processes, the 
quality of evidence generated during development, and the outcomes of clinical use of 
these products[129]. The FDA identified the “Critical Path” as a process beginning with 
identification of a drug candidate and completing in marketing approval. Along the path to 
the final marketing approval phase, the new drugs are subjected to a series of evaluations 
to predict its safety and effectiveness. The FDA sets three dimensions along the critical 
path, safety, medical utility and industrialization. Through the CPI, FDA applies scientific 
tools to improve drug development process and reduce uncertainty in each dimension. The 
candidate must successfully complete a series of evaluations of its potential safety and 
efficacy at each step of three dimensions along the critical path and must be amenable to 
mass production. Although CPI provides critical steps and sophisticated scientific tools 
along the path to the final approval phase, deconstructing and innovating the drug 
development process is still required[128-130].  
 
Thirdly, some previous research has been attempting to improve R&D productivity 
in drug development. Paul et al. defines R&D productivity as two important dimensions: 
R&D efficiency and R&D effectiveness[124]. They build a model of R&D productivity to 
understand the interdependencies between inputs, output and outcomes. They also suggest 
work in process, value, cycle time, cost, and probability of technical success as key areas 
for improving R&D productivity. Conclusively, they contrast new drug development 
paradigm to traditional pipeline along with concepts such as critical chain of project tasks, 
adaptive and seamless process design, and portfolio selection in which lead dynamic 
transaction of information and fast feedback on pathway to launch new drugs. Meanwhile, 
DiMashi suggests quick development and earlier termination decisions to reduce R&D cost 
and failure rate, so that company can reinvest savings to another agent[131]. He focuses on 
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improving attrition in early development phase and inducing decision making point shifted 
to earlier phase to save capitalized clinical cost. 
 
Another approach to innovate drug development and drug discovery is model-based 
approach. Lalonde et al. and Zhang et al. apply model-based drug development to focus on 
mathematical models to characterize the input-output relationship within disease and drug 
models for knowledge management and decision making[130, 132]. They suggest 
methodology to apply model-based drug development as three steps: knowledge gathering, 
model construction and simulation of outcome. This approach is similar to FDA’s CPI 
approach because it applies quantitative tools in each step and simulates model to clear 
uncertainty along the entire development process.  
 
Many previous researches have shown the clues for accelerating drug development 
and drug discovery. However, implementing new strategy in drug development requires 
practical process innovation to accelerate drug development. With the emphasis on 
acceleration, possible number of options can be considered. Lesko et al. suggests five 
options[133]: 1) paralleling or overlapping phases of clinical development, 2) intensifying 
efforts in a given phase of drug development, 3) combining multiple objectives and efforts, 
4) simplifying clinical programs and shortening timelines, 5) skipping or postponing 
studies. Taking FDA’s CPI into account, accelerating drug development should be placed 
on the deconstructing current process on first hand. Then, paralleling and combine each 
phase to facilitate accelerated drug development process is required.  
 
With this framework in mind, this paper aims to study drug development and drug 
discovery process, particularly identifying critical process to achieve the goal of each phase. 
Each big phase on the drug development pathway has its own agenda to achieve. Some 
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process steps strongly affect the goal but others are not. Specifically, we focus on three 
areas: 
 
1. Identify critical processes in each phase on drug development and drug 
discovery. Since drug development pathway consists of lots of steps to evaluate 
new drug’s safety and efficacy, we first focus on identify overall processes 
along the whole pathway. Then, we figure out critical processes in each phase 
to build parallel process model. 
 
2. Build critical process model to accelerate drug development and drug 
discovery. After identifying critical processes in each phase, we manage to 
connect each critical processes taking paralleling and intensifying processes 
into account. As a result, general drug development model and critical path drug 
development model can be presented and compared. Then, we focus on the 
variations between the two development models.  
 
 
3. Suggest possible scenarios to reduce cycle time from beginning to marketing in 
drug development and drug discovery. Based on both general drug development 
and critical path drug development models, we aim to show possible scenarios 
to reduce total cycle time to complete drug development processes using 
computerized simulation model.  
 
4.1.2 Drug Development Process Model 
 
New drug development can proceed along varied pathways for different compounds, but a 
development paradigm has been articulated that has long served well as a general 
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model[134]. In outline form, the paradigm portrays new drug development as proceeding 
in a sequence of phases. The process and time course from drug discovery to approval for 
marketing is shown in Figure 4-1. 
 
 
Figure 4- 1. The New Drug Development Process[135] 
 
 
This paper studies sequence of phases in new drug development as: (1) preclinical 
research, (2) IND review, (3) clinical research and (4) NDA review. All processes would 
be applied to develop new drug under general principle even though they could be skipped 
and modified according to types of drug. 
 
 




As part of the drug discovery process, using chemical library profiling and lead compound 
optimization, the many thousands of compounds synthesized and tested in high-throughput 
biological activity screens are narrowed down to relatively few compounds that will be 
evaluated in Phase 1. The purpose of the preclinical phase is to further narrow drug 
candidate selection for subsequent evaluation in humans. This is achieved through in 
discovery, formulation study, efficacy study, safety study, and animal testing. A broad, 
general goal is to integrate knowledge gained from this phase into the decision-making 
process in the design and conduct of early clinical studies. When it occurs and is 
bidirectional, this integrative process provides a better understanding of the mechanism of 
drug action, suggests improved animal models to evaluate drug targets and drug-disease 
interactions, and helps to design animal experiments that, as second-generation compounds 
are studied, provide more clinically useful information, predict drug class liability with 
respect to safety, and generate exposure-response relationships for efficacy and safety that 
can be extrapolated from animals to humans. 
 
The first step of preclinical phase is target discovery, which focuses on 
understanding the disease targets. Target discovery is highly depending on a detailed 
knowledge of the disease and it involves target isolation and purification, in vitro and in 
vivo assay development and testing of compounds. During the target discovery process, 
new drug substances are identified through target identification, screenings, structure 
modification and formulation study. Once new drug substances are found, two types of 
preclinical research need to be done: pre-clinical efficacy evaluation and preclinical safety 
evaluation. Both processes are biochemical evaluations to ensure effectiveness and safety 
subject to animals. In preclinical efficacy evaluation, pharmacology study, 
pharmacokinetics(PK) study and pharmacodynamics(PD) study are main tasks. If the 
efficacy evaluation is not satisfied, then the new drug substances would be revisited on 
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formulation study and they would be modified to enhance efficacy. Likewise, over the pre-
clinical safety evaluation, toxicity study, ADME(absorption, distribution, metabolism, 
excretion) test, and chronic toxicity study are performed.  
 
As a promising new drug substances are characterized for biological activity, they 
are also evaluated with regard to chemical and physical properties that have bearing on its 
ultimate and successful formulation into stable and effective pharmaceutical products 
before formulating initial products. In this early formulation study, preformulation tests 
such as drug solubility, partition coefficient, dissolution rate, physical form and stability 
are evaluated to support producing initial products. In the meantime, the sponsor of new 
drug is preparing IND review and research agency is preparing for Phase 1 and Phase 2 for 
clinical trials. 
 












Preclinical research:  
Safety 
Acute Toxicity Study 
Subacute Toxicity Study 
Chronic Toxicity Study 
Reproduction/Mutagenicity Study 
Preclinical research:  
Early formulation study 
Drug Solubility Test 
Partition Coefficient Test 
Dissolution Rate Test 





Under the Food, Drug, and Cosmetic Act as amended, the sponsor of a new drug is required 
to file with the FDA an Investigational New Drug Application(IND) before the drug may 
be given to human subjects. This is to protect the rights and safety of the subjects and to 
ensure that the investigational plan is sound and is designed to achieve the stated 
objectives[135]. When the IND is received by the FDA, the IND is forwarded to 
appropriate division and the content of the application is thoroughly reviewed to determine 
whether the preclinical data indicates that the new drug is sufficiently safe for 
administration to human subjects and that the proposed clinical studies are designed to 
provide the desired data on drug safety and efficacy while not exposing the human subjects 
to unnecessary risks. The IND review has “30-day Response Clock” policy that FDA is 
required by the Modernization Act to respond in writing to an IND sponsor within 30 
calendar days of receipt of the sponsor’s complete response to a clinical hold[81]. Figure 
4-3 shows the IND review process. 
 
 






Clinical research typically proceeds through three successive phase[134]. In Phase I, a 
small number of usually healthy volunteers are tested to establish safe dosages and to 
gather information on the absorption, distribution, metabolic effects, excretion, and toxicity 
of the compound. Phase I is sometimes split into two steps with regard to amount of 
dosages. The first step of Phase I is single ascending dose(SAD) study, which is small 
groups of subjects are given a single dose of the drug while they are observed and tested 
for a period of time to confirm safety[137]. Typically, a small number of participants, 
usually three, are entered sequentially at a particular dose. If they do not exhibit any adverse 
side effects, and the pharmacokinetic data are roughly in line with predicted safe values, 
the dose is escalated, and a new group of subjects is then given a higher dose. If 
unacceptable toxicity is observed in any of the three participants, an additional number of 
participants, usually three, are treated at the same dose. This is continued until pre-
calculated pharmacokinetic safety levels are reached, or intolerable side effects start 
showing up at which point the drug is said to have reached the maximum tolerated 
dose[138]. The second step of Phase I is multiple ascending dose(MAD) study that studies 
investigate the pharmacokinetics and pharmacodynamics of multiple doses of the drug, 
looking at safety and tolerability. In these studies, a group of patients receives multiple low 
doses of the drug, while samples are collected at various time points and analyzed to 
acquire information on how the drug is processed within the body. The dose is subsequently 
escalated for further groups, up to a predetermined level[137]. While MAD study is on 
progress, food effect test could be designed to investigate any differences in absorption of 
the drug by the body, caused by eating before the drug is given. If Phase I studies 
demonstrate sufficient merit and if the order of drug toxicity is low enough, Phase II begins, 




Phase II is conducted with subjects who have the targeted disease or condition and 
are designed to obtain evidence on safety and preliminary data on efficacy[134]. Phase II 
is also divided into two steps like Phase I studies. The former part of Phase II is pilot study 
which is specifically designed to assess dosing requirements and the latter part of Phase II 
is pivotal study which is specifically designed to study efficacy. During Phase II studies, 
the new drug product is refined, with the final formulation developed for use during Phase 
III studies. 
 
The final Phase III typically consists of a number of large-scale trials that are 
designed to assess the effectiveness of the new intervention and, thereby, its value in 
clinical practice. Many additional clinicians having patients with the condition for drug’s 
intended use are recruited to participate in this study. Several dosage strengths of the 
proposed new drugs may be evaluated during this Phase III, using formulations intended 
to be proposed in the new drug application(NDA) and for marketing[135]. Sufficient 
information on the new drug’s effectiveness and safety is expected to be collected during 
Phase III. 
 
Table 4- 2. Process of Clinical Research 
Process Tasks 
Clinical Research: Phase I 
SAD Test 
MAD Test 
Food Effect Test 
Clinical Research: Phase II 
Pilot Study in Phase II 
Pivotal Study: Efficacy Test 
Clinical Research: Phase III 
Pivotal Study in Phase III 





The New Drug Application 
If the three clinical phases during the IND period demonstrate sufficient drug safety and 
therapeutic effectiveness, the sponsor may fila a NDA with the FDA. The completed NDA 
is carefully reviewed by the FDA, which decides whether to allow the sponsor to market 
the drug, to disallow marketing, or to require additional data before rendering a 
judgement[135]. By regulation, the FDA must respond within 180 days of receipt of an 
application[137]. However, it generally takes more than 6 months for sponsor to fulfill the 
requirement of the NDA, sometimes takes up to 7 years to get the approval to market the 
drug[125, 137]. Figure 4. shows the NDA review process. 
 
 
Figure 4- 4. The NDA Review Process 
 
4.1.3 Critical Path Model and Simulation Study 
 
Simulation Results from Current Sequences of the New Drug Development Process 
In this part, we first attempt to run current new drug development process suggested in 
section 2. Taking into account of deconstructing of new drug development[130, 139, 140], 
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optimizing drug development strategy[81, 132, 141], and productivity[124, 125, 129, 131], 
we aim to two simulation models: from beginning to the IND review and from beginning 
to the completion of the NDA review. The former simulation model could help the 
pharmaceutical companies to make early termination of the new drug development and the 
latter model could spotlight overall R&D time consuming if they maintain to adopt the 
series of current new drug development process.  
 
Statistics and anticipated times consuming on the tasks of new drug development 
process are gathered from various sources[135, 137, 138, 142] and experts from 
pharmaceutical industry. Collecting process time, we decide some of the process times as 
fixed number if they maintain very minimum variations while we set triangular, normal or 
uniform distributions to the process times if they are highly volatile. All distribution sets 
are determined with reasonable considerations among researchers. Table 4-3 shows 
simulation input table and Table 4-4 shows success rate of each test. 
 
Table 4- 3. Simulation Input Table 
Process Tasks Time Distribution(days) 
Discovery 
High-Throughput Screening Avg. 4~6 weeks Triangular(28, 42, 38) 
Structure/Molecular 
Modification 
Avg. 3 ~ 5 weeks Triangular(20, 27, 33) 
Mechanism-Based Design Avg. 2 weeks 




In-Vitro Testing 14 days Fixed Delay 
In-Vivo Testing 28 days Fixed Delay 
ADME Testing 5 -10 days Fixed Delay: 7 days 
Pharmacodynamics Study Avg. 2 weeks Normal (14, 2) 
Pre-clinical 
research: Safety 
Acute Toxicity Study Avg. 1 day 
Triangular(0.5, 1.2, 1) 
Normal(1, 0.9) 
Uniform(0.5, 1.2) 
Subacute Toxicity Study Avg. 2 weeks 
Triangular(12, 16, 14) 
Normal(14, 2) 
Uniform(12, 16) 
Chronic Toxicity Study 90 ~ 180 days Triangular(90, 180, 160) 
100 
 




Up to 18 ~ 24 
months 





Drug Solubility Test Avg. 1 month Fixed Delay: 30 days 
Partition Coefficient Test Avg. 1 month Fixed Delay: 30 days 
Dissolution Rate Test Avg. 1 month Fixed Delay: 30 days 
Physical Form Test Avg. 1 month Fixed Delay: 30 days 
Stability Test Avg. 1 month Fixed Delay: 30 days 
IND Review IND Review 30 days Fixed Delay 
Clinical research: 
Phase 0 
Pre-Clinical Research Test 30 ~ 60 days Triangular(30, 60, 50) 
Clinical research: 
Phase 1 
SAD Test 180 ~ 240 days Triangular(180, 240, 215) 
MAD Test 180 ~ 240 days Triangular(180, 240, 212) 
Food Effect Test Avg. 60 days Uniform(50, 70) 
Clinical research:  
Phase 2 
Pilot Study in Phase 2 150 ~ 180 days Triangular(90, 180, 160) 
Pivotal Study: Efficacy Test 180 ~ 720 days Triangular(180, 720, 600) 
Clinical research:  
Phase 3 
Pivotal Study 360 ~ 1100 days Triangular(360, 1100, 850) 
Additional Study for Regime Avg. 1 month Fixed Delay: 30 days 
Long-term Study 360 ~ 2160 days Triangular(360, 2160, 1790) 
NDA Review NDA Review Avg. 540 days 
Uniform(500, 600) 
Triangular(480, 660, 550) 
 
Table 4- 4. Success rate of each test 
Decision Nodes Success Rate 
Discovery Test 10~25% 
Efficacy Test 5~12% 
Safety Test 3~9% 
 
We generate 3 cases with respect to combinations of simulation input table: the 
shortest, the moderate, and the longest case. The success rate is randomly generated within 
given range in Table 4-4. Each case generates the expected processing time with at least 
100 replications in simulation. The first simulation model which covers from beginning to 
the IND review completion results in 60 months for the shortest case, 64 months for the 
moderate case and 72 months for the longest case. The second simulation model which 
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covers from beginning to the NDA review completion provides outcome results as 180 
months for the shortest case, 182 months for the moderate case and 199 months for the 
longest case. These timelines are similarly compatible with various research[123, 125, 129, 
135] but longer than DiMasi et al[134]. Since DiMasi et al. found the average length of 
processing time from a survey of 10 pharmaceutical firms[134] while our simulation model 
suggests average length of processing time based on simulation generated with stochastic 
distribution, it might be different from each other with the nature of study scheme. 
 
Table 4- 5. Simulation results from current new drug development process 
Beginning to the 
IND review 
Completion 
Case Shortest Moderate Longest 
Months 60 months 64 months 72 months 
Days 1,807 days 1,915 days 2,161 days 
Range 1,756 ~ 1,900 days 1,800 ~ 1,975 days 2,092 ~ 2,400 days 
Beginning to the 
NDA review 
Completion 





(15 years 2 months) 
199 months 
(16 years 7 months) 
Days 5,411 days 5,441 days 5,972 days 
Range 5,263 ~ 5,568 days 5,355 ~ 5,530 days 5,708 ~ 6,915 days 
 
 
Simulation Results from Parallel Model of the New Drug Development Process 
After the demonstrating of the current new drug development process according to two 
simulation models, we find the critical path tasks to be centered in order to build parallel 
model. We adopt two principles to identify critical path and build parallel process. First of 
all, we figure out bottleneck tasks to delay total processing time. Since the bottleneck tasks 
make other tasks starving from global system viewpoint, we build parallel process 
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conducting some tasks simultaneously during performing bottleneck task. Secondly, we 
identify parallel model taking into account of not to break the exact sequences of the new 
drug development process. For example, even though certain tasks could be hooked up 
with bottleneck task, they might require prerequisite task to move on. In other words, we 
sort out each task as either possible candidate of parallel model or candidate to be 
conducted standalone. Table 4-6 presents summary of tasks in parallel model, which 
explains what tasks can be conducted simultaneously. Also, Figure 4-5 shows the critical 
path flow in the new drug development process. In Figure 4-5, the tasks marked with same 
color would be conducted simultaneously under parallel model. 
 
Table 4- 6. Summary of tasks in parallel model 
Parallel Group Tasks Bottleneck 
High-Throughput Screening 
High-Throughput Screening Structure/Molecular Modification 
Mechanism-Based Design 
In-Vitro Testing 
ADME Testing In-Vivo Testing 
ADME Testing 
Acute Toxicity Study 
Reproduction/Mutagenicity Study Subacute Toxicity Study 
Reproduction/Mutagenicity Study 
Drug Solubility Test 
All Simultaneous Tasks 
Partition Coefficient Test 
Dissolution Rate Test 
Physical Form Test 
Stability Test 
IND Review 
Pre-Clinical Research Test 
Pre-Clinical Research Test 




Table 4- 6. Continued 
Food Effect Test  
Pilot Study in Phase 2 
Pivotal Study: Efficacy Test 
Pivotal Study: Efficacy Test 
Pivotal Study 
Long-term Study Additional Study for Regime 
Long-term Study 




Figure 4- 5. Critical path flow in the new drug development process 
 
Then, we run the two simulation models again based on parallel model with critical 
path to highlight the cycle time reduction. We apply same simulation input for the 3 cases 
and the success rate is randomly generated. Likewise, each case produces the expected 
processing time with at least 100 replications in simulation. Particularly, we examine the 
possibility whether the parallel model could achieve 36 months’ range to complete up to 
the IND review task because we want to ensure that our model would be meaningful system 
to apply “quick win, fail fast” paradigm[124]. The first simulation model which covers 
from beginning to the IND review completion shows 30 months for the shortest case, 36 
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months for the moderate case, and 39 months for the longest case, that all results are 
generally satisfied with 36 months’ cut considering nature of stochastic distribution. The 
second simulation model which covers from beginning to the NDA review completions 
results in 116 months for the shortest case, 130 months for the moderate case and 160 
months for the longest case, that 20% ~ 36% of total cycle time reductions are expected 
with parallel model. 
 
Table 4- 7. Simulation results from parallel model of the new drug development process 
Beginning to the 
IND review 
Completion 
Case Shortest Moderate Longest 
Months 30 months 36 months 39 months 
Days 908 days 1,081 days 1,168 days 
Range 808 ~ 1,000 days 889 ~ 1,201 days 989 ~ 1,302 days 
Beginning to the 
NDA review 
Completion 
Case Shortest Moderate Longest 
Months 
116 months 
(9 years 8 months) 
130 months 
(10 years 10 months) 
160 months 
(13 years 4 months) 
Days 3,468 days 3,912 days 4,792 days 










We have described the first in-silico drug design system model to accelerate drug discovery. 
Our model spans preclinical research, the IND review, clinical research, and the NDA 
review. We first have identified the global process to be applied for any drug discovery 
path and then assigned time frame over the span. The estimated cycle time from computer 
simulations until completing the IND review would be more than 5 years and until getting 
approval of the NDA review would be more than 15 years, possibly more than 16 years if 
the new drug development process follows serial sequences. These simulation results prove 
why numerous attempts to accelerate the new drug development process have been done 
for the past two decades. In particular, the fact that faster development of the new drug 
reduces capitalized costs[131] has been shown empirically and improvements in the timing 
of early research termination on new drug are required under the circumstance that industry 
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clinical success rates have remained stable for a long time[8], it is clear that contributing 
solutions to achieve rapid drug development should be addressed.  
 
Since identification and optimization of the critical path of the development 
tasks[124], telescoping and overlapping of development process[133], model-based drug 
development[130, 132, 140], and deconstructing the drug development process[129, 139] 
have been suggested as potential solutions, we try to identify bottlenecks, and perform 
system optimization that offers a holistic view of discovery pathways. The integration of 
bottlenecks into possible candidate tasks which can be conducted simultaneously 
highlights critical paths for the accelerated development process. We define the critical 
paths as parallel model for the new drug development. To verify effectiveness of our 
parallel model, we simulate two models, one for decision making of early termination and 
the other for the overall paths from start to registration of a new drug. Computer simulations 
show that parallel models up to the IND review reduce at least 40% processing time 
compare to serial sequence models, even up to 60% reduction could be possible. Also, 
simulations demonstrate that parallel models up to the NDA review reduce 20% to 36% 
ranges of total processing time compare to serial sequence models. Since empirical data 
suggests that 30% of phase-time reduction could induce about 20% of cost reduction, we 
believe that our parallel model would allow not only rapid development but also 
minimizing risk, cost, and time.  
 
For the further study, we would like integrate our parallel model into R&D 
productivity and total cost measurement framework. This research focuses on processing 
time up to certain points on the new drug development pathways and measures risks and 
cost savings indirectly from empirical research. However, our computational model can 
generate productivity measures such as utilization rate and anticipate cost along with the 
development pathways. Therefore, we firmly believe that our model would be flexibly 
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